METHOD FOR THE TREATMENT OF A DISEASE MEDIATED BY T-LYMPHOCYTES

Abstract

The present invention relates to the field of medicine, and more particularly to a method for treating a disease or disorder mediated by T-lymphocytes bearing a TRBV9 segment within the T-cell receptor, which includes administering an anti-TRBV9 antibody in specific doses and dosage regimens, and further relates to the use of an anti-TRBV9 antibody to treat a disease or disorder mediated by T-lymphocytes bearing a TRBV9 segment within the T-cell receptor, where the anti-TRBV9 antibody is administered in specific doses and dosage regimens.

Description

[0001] METHOD FOR THE TREATMENT OF A DISEASE MEDIATED BY T-LYMPHOCYTES

[0002] Field of technology to which the invention relates

[0003] The present invention relates to the field of medicine, namely to a method for treating a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in a T-cell receptor, comprising administering an anti-TKVV9 antibody using certain doses and administration regimens; to using an anti-TKVV9 antibody for treating a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in a T-cell receptor, where the anti-TKVV9 antibody is administered using certain doses and administration regimens.

[0004] State of the art

[0005] Autoimmune diseases are caused by autoreactive T lymphocytes (Haroon N et al., Arthritis Rheum. 2013 Oct; 65(10):2645-54., Duarte J. et al., PloS One 2010 May 10; 5(5):el0558; Konig M. et al., Front Immunol 2016 Jan 25; 7:11). The interaction of the antigen-recognizing T cell receptor (TCR) with proteins of the major histocompatibility complex (MHC, HLA), which present processed peptides of intracellular proteins or proteins of pathogenic organisms on their surface, plays a key role in the emergence of autoreactive T lymphocyte clones. A number of autoimmune diseases are associated with the presence of a certain variant of the HLA gene in a person. Thus, the HLA-B27 allele is associated with ankylosing spondylitis, reactive arthritis and Crohn's disease.The risk of developing autoimmune diseases in carriers of certain allelic variants of HLA may be explained by the preferential presentation by these alleles of certain peptides, which are autoantigens, the immune response against which initiates the development of an autoimmune disease. One of the possible mechanisms for the development of an autoimmune reaction is the presentation by molecules of the histocompatibility complex of peptides from proteins of bacterial or viral origin, homologous to the body's own peptides, which can lead to the development of an immune response against its own antigens due to cross-reactivity.

[0006] It is known from the state of the art that the marker that allows identifying the clone of T-lymphocytes involved in the pathogenesis of an autoimmune disease is the sequence of the T-cell receptor (TCR). The subunits of T-cell receptors structurally belong to the superfamily of immunoglobulins and are formed from several gene segments. The variable regions of TCR form the antigen-binding center of TCR. This means that they are clone-specific, i.e. they differ in T-lymphocytes that react to different antigens.

[0007] T lymphocytes (T cells) are stimulated when antigens bind to their T cell receptors (TCRs). The TCR, the defining structure of T cells, is a transmembrane heterodimer consisting of either alpha and beta chains or delta and gamma chains joined by a disulfide bond. Within these chains are complementary determining regions (CDRs) that determine the antigen that the TCR will bind. TCR development occurs through a lymphocyte-specific process of gene recombination that assembles a final sequence from a large number of potential segments. This genetic recombination of TCR gene segments in somatic T cells occurs early in thymus development. The TCRa gene locus contains variable (V) and joining (J) gene segments (Va and Ja), whereas the TCRP locus contains the D gene segment in addition to the VP and jp segments. Accordingly, the a-chain is generated by VJ recombination, and the P-chain is involved in VDJ recombination.

[0008] The TCR a chain gene locus consists of 46 variable segments (TRAV), 8 joining segments (TRAJ), and a constant region. The TCR p chain gene locus consists of 48 variable segments (TRBV), followed by two diversity segments (TRBD), 12 joining segments (TRBJ), and two constant regions (Bio-Rad. Mini-review | An overview of T cell receptors [Electronic resource] / / Bio-Rad. URL: https: / / www.bio-rad-antibodies.com / t-cell-receptor-minireview.html (accessed: 24.04.2020)).

[0009] Currently, a significant amount of data has been accumulated indicating that the development of HEA-B27-associated diseases is caused by the expansion of antigen-specific clones of T-lymphocytes.

[0010] A consensus variant of autoimmune TCRs in ankylosing spondylitis (radiographic axial spondyloarthritis) has been described; it has been shown to be present in synovial fluid and peripheral blood of patients with ankylosing spondylitis and to be absent at the same depth of analysis in healthy donors, regardless of the HLA*B27 allele status (Faham M. et al., Arthritis Rheumatol. 2017; 69(4):774-784; Komech E et al. 12th EJI-EFIS Tatra Immunology Conference; 2016 Sep 3-7; Strbske Pleso, Slovakia. Abstract book p. 39). These TCRs belong to the TRBV9 family (according to the IMGT nomenclature).

[0011] T-cell receptors bearing beta chains of the TRBV9 family have also been shown to be involved in the development of such an autoimmune disease as celiac disease (Petersen J et al., J Immunol. 2015; 194(12): 6112-22). They are also found on the surface of T cells susceptible to malignancy in the case of T-cell lymphomas and T-cell leukemias, including T-cell lymphoma caused by the Epstein-Barr virus (EBV) (Toyabe S et al., Clin Exp Immunol. 2003; 134(1): 92-97).

[0012] Taking into account the above, the TRBV9 protein may serve as a target for a cytotoxic monoclonal antibody that will induce the depletion of TRBV9+ T lymphocytes (TRBV9-positive T lymphocytes), including pathogenic autoreactive T lymphocyte clones.

[0013] In connection with the above, it is relevant to develop a method for treating a disease or disorder mediated by the human T-cell receptor carrying TRBV9, including the administration of anti-TRBV9 antibodies using specific doses and administration regimens.

[0014] Brief description of the drawings

[0015] Figure 1 is a diagram of the main processes taken into account in the mathematical model.

[0016] TCR - T-Cell Receptor,

[0017] Effector cell - effector cell.

[0018] Detailed description of the invention

[0019] Definitions

[0020] Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings commonly understood by those skilled in the art. Furthermore, unless the context otherwise requires, singular terms include plural terms, and plural terms include singular terms.

[0021] In the present description and in the following claims, unless the context otherwise requires, the words “have,” “include,” and “comprise,” or variations thereof such as “has,” “having,” “includes,” “including,” “comprises,” or “containing,” are to be understood as including the stated whole or group of wholes, but not excluding any other whole or group of wholes.

[0022] The term "antibody" or "immunoglobulin" (Ig) includes full-length antibodies or any antigen-binding fragment (i.e., "antigen-binding portion") or individual chains thereof. The term "antibody" as used herein is used in the broadest sense and may include, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, humanized, fully human antibodies, and chimeric antibodies.

[0023] A full-length antibody is a glycoprotein containing at least two heavy (H) chains and two light (L) chains linked by disulfide bonds. Each heavy chain contains a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The constant region is identical in all antibodies of the same isotype but differs between antibodies of different isotypes. Heavy chains γ, α, and δ contain a constant region that consists of three constant domains, CHI, CH2, and CH3 (arranged in a row), and a hinge region that imparts flexibility (Woof G, Burton D, Nat Rev Immunol 4 (2004) pp. 89-99). Only two types of light chains are known in mammals, designated lambda (X) and kappa (k). Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The approximate length of a light chain is 211-217 amino acids.Preferably, the light chain is a lambda (X) light chain and the CL constant domain is preferably a C-lambda (X).

[0024] The VH and VL regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), sandwiched between regions that are more conserved, called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain the binding domain that interacts with antigen. The constant regions of antibodies can mediate the binding of immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

[0025] The term "antigen-binding portion" of an antibody or "antigen-binding fragment" as used herein refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. As used herein, an "antigen-binding fragment" refers to a Fab fragment, i.e., a monovalent fragment consisting of the VL, VH, CL, and CH1 domains that is linked to an Fc fragment monomer. The term "variable" refers to the fact that certain segments of the variable domains vary widely in sequence among antibodies. The V domain mediates antigen binding and determines the specificity of a particular antibody for its particular antigen. However, the variability is not uniformly distributed over the 110 amino acid region of the variable domains.In contrast, V regions consist of invariant fragments called framework regions (FRs) of 15–30 amino acids separated by shorter regions of extreme variability called hypervariable regions or CDRs. Each variable domain of native heavy and light chains contains four FRs, generally adopting a beta-sheet configuration, linked by three hypervariable regions that form loops that link and, in some cases, are part of a beta-sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions of the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest. 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)).Constant domains are not directly involved in antibody-antigen binding, but exhibit various effector functions, such as the involvement of the antibody in antibody-dependent cellular cytotoxicity (ADCC).

[0026] The term "hypervariable region" as used herein refers to the amino acid residues of an antibody that are responsible for antigen binding. Typically, the hypervariable region contains amino acid residues from the "complementarity determining region" or "CDR" and / or those residues from the "hypervariable loop".

[0027] "Kabat nomenclature" or "Kabat nomenclature" is used herein to refer to a system of numbering amino acid residues that are more variable (i.e., hypervariable) than the rest of the amino acid residues in the variable regions of the heavy and light chains of an antibody (Kabat et al. Ann. NY Acad. Sci., 190:382-93 (1971); Kabat et al. Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242 (1991)).

[0028] An antibody of the present invention "which binds" a target antigen is an antibody that binds the antigen with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent when targeting a protein or a cell or tissue expressing the antigen, and cross-reacts with other proteins to a small extent. In such embodiments, the degree of binding of the antibody to a protein other than the "target" (an "off-target protein") is less than 10% of the binding of the antibody to the specific target protein, as determined by fluorescence-activated cell sorting (FACS), radioimmunoprecipitation (RIA), or ELISA.With respect to the binding of an antibody to a target molecule, the term "specific binding" or the expressions "specifically binds to" or "specific for" a particular polypeptide or epitope on a particular target polypeptide means binding that is measurably different from non-specific interaction.

[0029] Specific binding can be determined quantitatively, for example, by determining the binding of a molecule compared to the binding of a control molecule. For example, specific binding can be determined by a competitive reaction with another molecule similar to the target, for example, with an excess of unlabeled target. In this case, specific binding is indicated if the binding of the labeled target to the probe is competitively inhibited by the excess of unlabeled target.As used herein, the term "specific binding" or the expressions "specifically binds to" or "specific for" a particular polypeptide or epitope on a particular target polypeptide may be characterized by an example of a molecule having a KD (affinity constant) for the target of at least about 200 nM, or at least about 150 nM, or at least about 100 nM, or at least about 60 nM, or at least about 50 nM, or at least about 40 nM, or at least about 30 nM, or at least about 20 nM, or at least about 10 nM, or at least about 8 nM, or at least about 6 nM, or at least about 4 nM, or at least about 2 nM, or at least about 1 nM or higher.In one embodiment of the invention, the term "specific binding" refers to binding in which a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or epitope on the polypeptide.

[0030] The term "monoclonal antibody" or "mAb" refers to an antibody that is synthesized and secreted by a distinct clonal population of cells.

[0031] The term "recombinant antibody" means an antibody that is expressed in a cell or cell line containing a nucleotide sequence(s) that encodes the antibody, wherein said nucleotide sequence(s) is(are) not associated with the cell in nature.

[0032] The term "isolated" as used to describe the various antibodies of the invention means an antibody that has been identified and separated and / or recovered from the cell or cell culture in which it is expressed. Contaminants from the natural environment are materials that typically interfere with the diagnostic or therapeutic use of the polypeptide and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. Typically, an isolated polypeptide is obtained by at least one purification step.

[0033] The terms "anti-TRBV9 antibody", "anti-TRBV9 antibody", "antibody that specifically binds to the beta chain of the TRBV9 family" or "anti-TRBV9 family beta chain antibody" and the like are used interchangeably within the scope of the present invention and refer to an antibody that specifically binds to an epitope of the beta chain of the TRBV9 family of the human T-cell receptor.

[0034] The term "primary dose" means the recommended dose of anti-TKVU9 antibody preparation, or the full recommended dose of anti-TKVU9 antibody preparation, or the recommended dose of anti-TKVU9 antibody preparation as an intravenous infusion, or the full recommended dose of anti-TKVU9 antibody preparation as an intravenous infusion.

[0035] The term "half of the primary dose" means half of the recommended dose of anti-TRBV9 antibody, or half of the full recommended dose of anti-TRBV9 antibody, or half of the full recommended dose of anti-TRBV9 antibody given as an intravenous infusion, or half of the full recommended dose of anti-TRBV9 antibody given as an intravenous infusion.

[0036] The term "at least" in the context of administration means the minimum value of the administration interval ±2 days. "At least 3 months" means administration after 3 months ±2 days, or 6 months ±2 days, or 9 months ±2 days, or 12 months ±2 days and so on in multiples of 3 months ±2 days. "At least 6 months" means administration after 6 months ±2 days, or 9 months ±2 days, or 12 months ±2 days and so on in multiples of 3 months ±2 days. "At least 9 months" means administration after 9 months ±2 days, or 12 months ±2 days, or 15 months ±2 days and so on in multiples of 3 months ±2 days. “At least 12 months” means administration at 12 months ±2 days, or 15 months ±2 days, or 18 months ±2 days, and so on in multiples of 3 months ±2 days.

[0037] The term "interval of administration" refers to the time interval between administrations, and subsequent administrations are counted from the date of the second or third infusion, and subsequently from each previous administration.

[0038] The term "first administration" or "first infusion" refers to the initial dose of anti-TKV9 antibody preparation or half of the main dose.

[0039] The term “second administration” or “second infusion” refers to the administration of the main dose of anti-TIVU9 antibody drug at least 3 months after the first administration.

[0040] The term “third administration” or “third infusion” refers to the administration of the main dose of anti-TIVU9 antibody at least 3 months after the second administration.

[0041] The term "subsequent administration" refers to administration of the main dose of anti-TKV9 antibody drug at least 3 months after each previous administration.

[0042] The term "use" refers to the possibility of using the anti-TKVU9 antibody according to the invention or a pharmaceutical composition containing it for the treatment, alleviation of the course of diseases or disorders, for accelerating remission, reducing the frequency of relapses of diseases or disorders.

[0043] The term "TRBV9-positive T-cell disease or disorder" means all diseases or disorders that are either directly or indirectly associated with TRBV9-positive T-cells, including the etiology, development, progression, persistence, or pathology of the disease or disorder.

[0044] The term "method of treatment" refers to the possibility of using the antibody according to the invention or a pharmaceutical composition containing it for the treatment, alleviation of the course of diseases, for accelerating remission, reducing the frequency of relapses due to diseases or disorders associated with the activity of T-lymphocytes bearing the TRBV9 segment in the T-cell receptor. "Treatment" or "treatment" of a disease, disorder or condition may include preventing or slowing the onset of clinical symptoms of a disease, disorder or condition developing in a person, inhibiting the disease, disorder or condition, i.e. stopping, reducing or slowing the progression of the disease or its relapse (in the case of maintenance therapy) or at least one clinical or subclinical symptom thereof, or alleviating or weakening the disease, i.e. causing regression of the disease, disorder or condition.As used herein, to "alleviate" a disease, disorder, or condition means to reduce the severity and / or frequency of the symptoms of the disease, disorder, or condition.

[0045] The present invention discloses methods for treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising administering an anti-TRBV9 antibody using certain doses and administration regimens. Furthermore, the present invention discloses uses of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the anti-TRBV9 antibody is administered using certain doses and administration regimens.

[0046] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying a TRBV9 segment in the T cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 0.03-10 mg / kg.

[0047] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying a TRBV9 segment in the T cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 0.03-7 mg / kg.

[0048] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying a TRBV9 segment in the T cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 0.3-7 mg / kg.

[0049] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying a TRBV9 segment in the T cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 1-7 mg / kg.

[0050] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 2-7 mg / kg.

[0051] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 3-7 mg / kg.

[0052] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 4-7 mg / kg.

[0053] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 5-7 mg / kg.

[0054] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 6-7 mg / kg.

[0055] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 1 mg / kg, or 2 mg / kg, or 3 mg / kg, or 4 mg / kg, or 5 mg / kg, or 6 mg / kg, or 7 mg / kg.

[0056] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 7.5 mg / kg, or 8 mg / kg, or 8.5 mg / kg, or 9 mg / kg, or 9.5 mg / kg, or 10 mg / kg.

[0057] In some embodiments, the anti-TKV9 antibody is administered at least every 3 to 12 months.

[0058] In some embodiments, the anti-TKV9 antibody is administered every 3 to 12 months.

[0059] In some embodiments, the anti-TKV9 antibody is administered at least every 6 to 12 months.

[0060] In some embodiments, the anti-TKVU9 antibody is administered every 6 to 12 months.

[0061] In some embodiments, the anti-TRBV9 antibody is administered at least every 3 months; or the anti-TRBV9 antibody is administered at least every 6 months; or the anti-TRBV9 antibody is administered at least every 9 months; or the anti-TRBV9 antibody is administered at least every 12 months. In some embodiments, the anti-TRBV9 antibody is administered every 3 months; or the anti-TRBV9 antibody is administered every 6 months; or the anti-TRBV9 antibody is administered every 9 months; or the anti-TRBV9 antibody is administered every 12 months.

[0062] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying a TRBV9 segment in the T cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 75-675 mg.

[0063] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying a TRBV9 segment in the T cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 100-650 mg.

[0064] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in the T cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 75-175 mg; or 200-300 mg; or 325-425 mg; or 450-650 mg; or 575-675 mg.

[0065] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in the T cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 100-150 mg; or 225-275 mg; or 350-400 mg; or 475-525 mg; or 600-650 mg.

[0066] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 115-135 mg; or 240-260 mg; or 365-385 mg; or 490-510 mg; or 615-635 mg.

[0067] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 120-130 mg; or 245-255 mg; or 370-380 mg; or 495-505 mg; or 620-630 mg.

[0068] In some embodiments, the anti-TKV9 antibody is administered at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

[0069] In some embodiments, the anti-TKV9 antibody is administered at least every 3 to 12 months.

[0070] In some embodiments, the anti-TKV9 antibody is administered every 3 to 12 months.

[0071] In some embodiments, the anti-TKV9 antibody is administered at least every 6 to 12 months.

[0072] In some embodiments, the anti-TKVU9 antibody is administered every 6 to 12 months.

[0073] In some embodiments, the anti-TKV9 antibody is administered at least every 3 months; or at least every 6 months; or at least every 9 months; or at least every 12 months.

[0074] In some embodiments, the anti-TKV9 antibody is administered every 3 months; or every 6 months; or every 9 months; or every 12 months.

[0075] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.03-10 mg / kg at least 3 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.03-10 mg / kg at least every 6 months.

[0076] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 3 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0077] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 6 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0078] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 9 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 9 months; or every 12 months.

[0079] In some embodiments of the invention, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 12 months.

[0080] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.03-7 mg / kg at least 3 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.03-7 mg / kg at least every 6 months.

[0081] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 3 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0082] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 6 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0083] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 9 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 9 months; or every 12 months.

[0084] In some embodiments of the invention, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 12 months.

[0085] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg at least 3 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg at least every 6 months.

[0086] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg 3 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg every 6 months; or every 9 months; or every 12 months. In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg 6 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0087] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 9 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg every 9 months; or every 12 months.

[0088] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg every 12 months.

[0089] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 1-7 mg / kg at least 3 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.3-7 mg / kg at least every 6 months.

[0090] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 1-7 mg / kg 3 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.3-7 mg / kg every 6 months; or every 9 months; or every 12 months. In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 1-7 mg / kg 6 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.3-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0091] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 9 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg every 9 months; or every 12 months.

[0092] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg every 12 months.

[0093] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.5-3.5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 1-7 mg / kg at least 3 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 1-7 mg / kg at least every 6 months.

[0094] In some embodiments, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a segment of TRBV9 in their T cell receptor, comprising first administering to a subject in need thereof an anti-TBV9 antibody at a dose equal to half the primary dose, 0.5-3.5 mg / kg, a second administration of the anti-TBV9 antibody at a primary dose of 1-7 mg / kg 3 months later, and subsequent administrations of the anti-TBV9 antibody at a primary dose of 1-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0095] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 6 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0096] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 9 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 9 months; or every 12 months.

[0097] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0098] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 1 mg / kg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 1 mg / kg at least every 6 months.

[0099] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 1 mg / kg 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 1 mg / kg every 6 months; or every 9 months; or every 12 months.

[0100] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 1 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 1 mg / kg every 6 months; or every 9 months; or every 12 months.

[0101] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 1 mg / kg after 9 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 1 mg / kg every 9 months; or every 12 months.

[0102] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 1 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 1 mg / kg every 12 months.

[0103] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 2 mg / kg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 2 mg / kg at least every 6 months.

[0104] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 2 mg / kg 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 2 mg / kg every 6 months; or every 9 months; or every 12 months.

[0105] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 2 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 2 mg / kg every 6 months; or every 9 months; or every 12 months.

[0106] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 2 mg / kg after 9 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 2 mg / kg every 9 months; or every 12 months.

[0107] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 2 mg / kg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 2 mg / kg every 12 months.

[0108] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 3 mg / kg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 3 mg / kg at least every 6 months.

[0109] In some embodiments, the method comprises a first administration of the anti-TKV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TKV9 antibody at a dose of 3 mg / kg 3 months later, and subsequent administrations of the anti-TKV9 antibody at a dose of 3 mg / kg every 6 months; or every 9 months; or every 12 months. In some embodiments, the method comprises a first administration of the anti-TKV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TKV9 antibody at a dose of 3 mg / kg 6 months later, and subsequent administrations of the anti-TKV9 antibody at a dose of 3 mg / kg every 6 months; or every 9 months; or every 12 months.

[0110] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 3 mg / kg after 9 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 3 mg / kg every 9 months; or every 12 months.

[0111] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 3 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 3 mg / kg every 12 months.

[0112] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 4 mg / kg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 4 mg / kg at least every 6 months.

[0113] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 4 mg / kg 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 4 mg / kg every 6 months; or every 9 months; or every 12 months.

[0114] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 4 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 4 mg / kg every 6 months; or every 9 months; or every 12 months.

[0115] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 4 mg / kg 9 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 4 mg / kg every 9 months; or every 12 months.

[0116] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 4 mg / kg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 4 mg / kg every 12 months.

[0117] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 5 mg / kg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 5 mg / kg at least every 6 months.

[0118] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 5 mg / kg 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 5 mg / kg every 6 months; or every 9 months; or every 12 months.

[0119] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 5 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 5 mg / kg every 6 months; or every 9 months; or every 12 months.

[0120] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 5 mg / kg 9 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 5 mg / kg every 9 months; or every 12 months.

[0121] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 5 mg / kg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 5 mg / kg every 12 months.

[0122] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 6 mg / kg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 6 mg / kg at least every 6 months.

[0123] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 6 mg / kg 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 6 mg / kg every 6 months; or every 9 months; or every 12 months.

[0124] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 6 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 6 mg / kg every 6 months; or every 9 months; or every 12 months.

[0125] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 6 mg / kg after 9 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 6 mg / kg every 9 months; or every 12 months.

[0126] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 6 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 6 mg / kg every 12 months.

[0127] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 7 mg / kg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 7 mg / kg at least every 6 months.

[0128] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 7 mg / kg 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0129] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 7 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0130] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 7 mg / kg after 9 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 7 mg / kg every 9 months; or every 12 months.

[0131] In some embodiments, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg every 12 months. In some embodiments, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0132] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 8 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0133] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 8 mg / kg 9 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 8 mg / kg every 9 months; or every 12 months.

[0134] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 8 mg / kg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 8 mg / kg every 12 months.

[0135] In some embodiments of the invention, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0136] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 9 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0137] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 9 mg / kg 9 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 9 mg / kg every 9 months; or every 12 months.

[0138] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 9 mg / kg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 9 mg / kg every 12 months.

[0139] In some embodiments of the invention, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0140] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 10 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0141] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 10 mg / kg 9 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 10 mg / kg every 9 months; or every 12 months;

[0142] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 10 mg / kg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 10 mg / kg every 12 months.

[0143] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 75-300 mg, a second administration of an anti-TKV9 antibody at a basal dose of 325-675 mg at least 3 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 325-675 mg at least every 6 months.

[0144] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 75-300 mg, a second administration of an anti-TKVU9 antibody at a basal dose of 325-675 mg 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a basal dose of 325-675 mg every 6 months; or every 9 months; or every 12 months.

[0145] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 75-300 mg, a second administration of the anti-TKVU9 antibody at a basal dose of 325-675 mg 6 months later, and subsequent administrations of the anti-TKVU9 antibody at a basal dose of 325-675 mg every 6 months; or every 9 months; or every 12 months.

[0146] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose of 75-300 mg, a second administration of the anti-TKVU9 antibody at a primary dose of 325-675 mg 9 months later, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 325-675 mg every 9 months; or every 12 months.

[0147] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose of 75-300 mg, a second administration of the anti-TKVU9 antibody at a basal dose of 325-675 mg 12 months later, and subsequent administrations of the anti-TKVU9 antibody at a basal dose of 325-675 mg every 12 months.

[0148] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in the T cell receptor, comprising a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-650 mg at least 3 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-650 mg at least every 6 months.

[0149] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 100-275 mg, a second administration of an anti-TKVU9 antibody at a basal dose of 350-650 mg 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a basal dose of 350-650 mg every 6 months; or every 9 months; or every 12 months.

[0150] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 100-275 mg, a second administration of an anti-TKVU9 antibody at a basal dose of 350-650 mg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a basal dose of 350-650 mg every 6 months; or every 9 months; or every 12 months.

[0151] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose of 100-275 mg, a second administration of the anti-TKVU9 antibody at a basal dose of 350-650 mg after 9 months, and subsequent administrations of the anti-TKVU9 antibody at a basal dose of 350-650 mg every 9 months; or every 12 months.

[0152] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 100-275 mg, a second administration of the anti-TKVU9 antibody at a basal dose of 350-650 mg 12 months later, and subsequent administrations of the anti-TKVU9 antibody at a basal dose of 350-650 mg every 12 months.

[0153] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least 3 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least every 6 months.

[0154] In some embodiments, the method comprises (i) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 3 months later, and subsequent administrations of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 6 months; or (j) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg after 3 months and subsequent administration of anti-TKVU9 antibody at a basic dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 9 months; or

[0155] (iii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 3 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months; or

[0156] (iv) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 6 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 6 months; or

[0157] (u) a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKVU9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 9 months; or

[0158] (vi) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 6 months later and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months; or (vii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg after 9 months and subsequent administration of anti-TKVU9 antibody at a basic dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 9 months; or

[0159] (viii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months; or

[0160] (ix) a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKVU9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months.

[0161] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least 3 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least every 6 months.

[0162] In some embodiments, the method comprises (i) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 3 months later, and subsequent administrations of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 6 months; or (j) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg after 3 months and subsequent administrations of anti-TKVU9 antibody at a basic dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 9 months; or

[0163] (iii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 3 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months; or

[0164] (iv) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 6 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 6 months; or

[0165] (u) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 6 months later and subsequent administrations of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 9 months; or (vi) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg after 6 months and subsequent administrations of anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months; or

[0166] (vii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 9 months; or

[0167] (viii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months; or

[0168] (ix) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 12 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months.

[0169] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment of a T cell receptor, comprising first administering to a subject in need thereof an anti-TBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of the anti-TBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 3 months later, and subsequent administrations of the anti-TBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least every 6 months.

[0170] In some embodiments, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment of a T cell receptor, comprising (i) a first administration to a subject in need thereof of an anti-TBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of the anti-TBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 3 months later, and subsequent administrations of the anti-TBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 6 months; or

[0171] (j) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 3 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 9 months; or

[0172] (iii) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 3 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months; or

[0173] (iv) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 6 months; or

[0174] (y) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 9 months; or

[0175] (vi) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months; or

[0176] (vii) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 9 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 9 months; or

[0177] (viii) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 9 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months; or

[0178] (ix) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months.

[0179] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg at least every 6 months.

[0180] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months.

[0181] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months.

[0182] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 9 months; or every 12 months.

[0183] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 370 mg every 12 months.

[0184] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg at least every 6 months.

[0185] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months.

[0186] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months.

[0187] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 9 months; or every 12 months.

[0188] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 375 mg every 12 months.

[0189] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg at least every 6 months.

[0190] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0191] In some embodiments, the method comprises a first administration of the anti-TKV9 antibody at a dose of 130 mg, a second administration of the anti-TKV9 antibody at a dose of 380 mg 6 months later; and subsequent administrations of the anti-TKV9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months. In some embodiments, the method comprises a first administration of the anti-TKV9 antibody at a dose of 130 mg, a second administration of the anti-TKV9 antibody at a dose of 380 mg 9 months later; and subsequent administrations of the anti-TKV9 antibody at a dose of 380 mg every 9 months; or every 12 months.

[0192] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 380 mg every 12 months.

[0193] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg at least every 6 months when the subject weighs between 30 and 50 kg.

[0194] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0195] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0196] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0197] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 370 mg every 12 months when the subject weighs between 30 and 50 kg.

[0198] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg at least every 6 months when the subject weighs between 30 and 50 kg.

[0199] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0200] In some embodiments, the method comprises a first administration of the anti-TKVY9 antibody at a dose of 125 mg, a second administration of the anti-TKVY9 antibody at a dose of 375 mg 6 months later; and subsequent administrations of the anti-TKVY9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months when the subject weighs from 30 to 50 kg. In some embodiments, the method comprises a first administration of the anti-TKVY9 antibody at a dose of 125 mg, a second administration of the anti-TKVY9 antibody at a dose of 375 mg 9 months later; and subsequent administrations of the anti-TKVY9 antibody at a dose of 375 mg every 9 months; or every 12 months when the subject weighs from 30 to 50 kg.

[0201] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 375 mg every 12 months when the subject weighs between 30 and 50 kg.

[0202] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg at least every 6 months when the subject weighs between 30 and 50 kg.

[0203] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0204] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0205] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0206] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 380 mg every 12 months when the subject weighs between 30 and 50 kg.

[0207] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg at least every 6 months.

[0208] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months.

[0209] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months.

[0210] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 9 months; or every 12 months.

[0211] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 495 mg every 12 months.

[0212] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg at least every 6 months.

[0213] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 6 months; or every 9 months; or every 12 months.

[0214] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 6 months; or every 9 months; or every 12 months.

[0215] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 9 months; or every 12 months.

[0216] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 500 mg every 12 months.

[0217] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg at least every 6 months.

[0218] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months.

[0219] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months.

[0220] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 9 months; or every 12 months.

[0221] In some embodiments, the method comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg 12 months later, and subsequent administrations of the anti-TKVU9 antibody at 505 mg every 12 months. In some embodiments, the method comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 495 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 495 mg at least every 6 months when the subject weighs between 51 and 89 kg.

[0222] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0223] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0224] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0225] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 495 mg every 12 months when the subject weighs between 51 and 89 kg.

[0226] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg at least every 6 months when the subject weighs between 51 and 89 kg.

[0227] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0228] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0229] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0230] In some embodiments, the method comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg 12 months later, and subsequent administrations of the anti-TKVU9 antibody at 500 mg every 12 months when the subject weighs from 51 to 89 kg. In some embodiments, the method comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 505 mg at least every 6 months when the subject weighs from 51 to 89 kg.

[0231] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0232] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0233] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0234] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 505 mg every 12 months when the subject weighs between 51 and 89 kg.

[0235] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg at least every 6 months.

[0236] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months.

[0237] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months.

[0238] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 9 months; or every 12 months.

[0239] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 620 mg every 12 months.

[0240] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg at least every 6 months.

[0241] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0242] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0243] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 9 months; or every 12 months.

[0244] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 625 mg every 12 months.

[0245] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg at least every 6 months.

[0246] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months.

[0247] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months.

[0248] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 9 months; or every 12 months.

[0249] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 630 mg every 12 months.

[0250] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg at least every 6 months when the subject weighs between 90 and 150 kg.

[0251] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg 3 months later.

[0252] T1 every 6 months; or every 9 months; or every 12 months if the subject weighs between 90 and 150 kg.

[0253] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0254] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0255] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 620 mg every 12 months when the subject weighs between 90 and 150 kg.

[0256] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg at least every 6 months when the subject weighs between 90 and 150 kg.

[0257] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0258] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0259] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0260] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 625 mg every 12 months when the subject weighs between 90 and 150 kg.

[0261] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg at least 3 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg at least every 6 months when the subject weighs between 90 and 150 kg.

[0262] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg 3 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0263] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg 6 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0264] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg 9 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0265] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at 630 mg every 12 months when the subject weighs between 90 and 150 kg.

[0266] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.03-10 mg / kg at least 3 months later, a third administration of the anti-TKV9 antibody at a primary dose of 0.03-10 mg / kg at least 6 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.03-10 mg / kg at least every 12 months.

[0267] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 3 months, a third administration of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 12 months.

[0268] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 6 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 12 months.

[0269] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 12 months.

[0270] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 12 months, a third administration of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 12 months.

[0271] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.03-7 mg / kg at least 3 months later, a third administration of the anti-TKV9 antibody at a primary dose of 0.03-7 mg / kg at least 6 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.03-7 mg / kg at least every 12 months.

[0272] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 3 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 12 months.

[0273] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 6 months, a third administration of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 12 months.

[0274] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 12 months.

[0275] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 12 months, a third administration of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 12 months.

[0276] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising first administering to a subject in need thereof an anti-TBV9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TBV9 antibody at a primary dose of 0.3-10 mg / kg at least 3 months later, a third administration of the anti-TBV9 antibody at a primary dose of 0.3-10 mg / kg at least 6 months later, and subsequent administrations of the anti-TBV9 antibody at a primary dose of 0.3-10 mg / kg at least every 12 months.

[0277] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TRBV9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TRBV9 antibody at a primary dose of 0.3-10 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at a primary dose of 0.3-10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 0.3-10 mg / kg every 12 months.

[0278] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 6 months, a third administration of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg every 12 months.

[0279] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 9 months, a third administration of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg every 12 months.

[0280] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 12 months, a third administration of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg every 12 months.

[0281] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising first administering to a subject in need thereof an anti-TBV9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TBV9 antibody at a primary dose of 0.3-7 mg / kg at least 3 months later, a third administration of the anti-TBV9 antibody at a primary dose of 0.3-7 mg / kg at least 6 months later, and subsequent administrations of the anti-TBV9 antibody at a primary dose of 0.3-7 mg / kg at least every 12 months.

[0282] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TRBV9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TRBV9 antibody at a primary dose of 0.3-7 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at a primary dose of 0.3-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 0.3-7 mg / kg every 12 months.

[0283] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg after 6 months, a third administration of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg every 12 months.

[0284] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg after 9 months, a third administration of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg every 12 months. In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg after 12 months, a third administration of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 0.3-7 mg / kg every 12 months.

[0285] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising first administering to a subject in need thereof an anti-TKV9 antibody at a dose equal to half the primary dose, 0.5-3.5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 1-7 mg / kg at least 3 months later, a third administration of the anti-TKV9 antibody at a primary dose of 1-7 mg / kg at least 6 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 1-7 mg / kg at least every 12 months.

[0286] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising a first administration to a subject in need thereof of an anti-TBV9 antibody at a dose equal to half the primary dose, 0.5-3.5 mg / kg, a second administration of an anti-TBV9 antibody at a primary dose of 1-7 mg / kg after 3 months, a third administration of an anti-TBV9 antibody at a primary dose of 1-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TBV9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0287] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.5-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 6 months, a third administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0288] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.5-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 9 months, a third administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0289] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.5-3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 12 months, a third administration of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0290] In some embodiments, the method comprises a first administration of the anti-TKV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TKV9 antibody at a dose of 1 mg / kg at least 3 months later, a third administration of the anti-TKV9 antibody at a dose of 1 mg / kg at least 6 months later, and subsequent administrations of the anti-TKV9 antibody at a dose of 1 mg / kg at least every 12 months. In some embodiments, the method comprises a first administration of the anti-TKV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TKV9 antibody at a dose of 1 mg / kg at 3 months, a third administration of the anti-TKV9 antibody at a dose of 1 mg / kg at 6 months; or at 9 months; or at 12 months; and subsequent administrations of the anti-TKV9 antibody at a dose of 1 mg / kg every 12 months.

[0291] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 1 mg / kg after 6 months, a third administration of an anti-TKVU9 antibody at a dose of 1 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 1 mg / kg every 12 months.

[0292] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 1 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a dose of 1 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 1 mg / kg every 12 months.

[0293] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 1 mg / kg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 1 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 1 mg / kg every 12 months.

[0294] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 2 mg / kg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 2 mg / kg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 2 mg / kg at least every 12 months.

[0295] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 2 mg / kg after 3 months, a third administration of an anti-TKVU9 antibody at a dose of 2 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 2 mg / kg every 12 months.

[0296] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 2 mg / kg after 6 months, a third administration of an anti-TKVU9 antibody at a dose of 2 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 2 mg / kg every 12 months.

[0297] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 2 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a dose of 2 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 2 mg / kg every 12 months.

[0298] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 2 mg / kg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 2 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 2 mg / kg every 12 months.

[0299] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 3 mg / kg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 3 mg / kg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 3 mg / kg at least every 12 months.

[0300] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 3 mg / kg after 3 months, a third administration of an anti-TKVU9 antibody at a dose of 3 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 3 mg / kg every 12 months.

[0301] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 3 mg / kg after 6 months, a third administration of an anti-TKVU9 antibody at a dose of 3 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 3 mg / kg every 12 months.

[0302] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 3 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a dose of 3 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 3 mg / kg every 12 months.

[0303] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 1.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 3 mg / kg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 3 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 3 mg / kg every 12 months.

[0304] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 4 mg / kg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 4 mg / kg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 4 mg / kg at least every 12 months.

[0305] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 4 mg / kg after 3 months, a third administration of an anti-TKVU9 antibody at a dose of 4 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 4 mg / kg every 12 months.

[0306] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 4 mg / kg after 6 months, a third administration of an anti-TKVU9 antibody at a dose of 4 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 4 mg / kg every 12 months.

[0307] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 4 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a dose of 4 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 4 mg / kg every 12 months.

[0308] In some embodiments, the method comprises a first administration of the anti-TKV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TKV9 antibody at a dose of 4 mg / kg 12 months later, a third administration of the anti-TKV9 antibody at a dose of 4 mg / kg 12 months later, and subsequent administrations of the anti-TKV9 antibody at a dose of 4 mg / kg every 12 months. In some embodiments, the method comprises a first administration of the anti-TKV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TKV9 antibody at a dose of 5 mg / kg at least 3 months later, a third administration of the anti-TKV9 antibody at a dose of 5 mg / kg at least 6 months later, and subsequent administrations of the anti-TKV9 antibody at a dose of 5 mg / kg at least every 12 months.

[0309] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 5 mg / kg after 3 months, a third administration of an anti-TKVU9 antibody at a dose of 5 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 5 mg / kg every 12 months.

[0310] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 5 mg / kg after 6 months, a third administration of an anti-TKVU9 antibody at a dose of 5 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 5 mg / kg every 12 months.

[0311] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 5 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a dose of 5 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 5 mg / kg every 12 months.

[0312] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 2.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 5 mg / kg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 5 mg / kg after 6 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 5 mg / kg every 12 months.

[0313] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 6 mg / kg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 6 mg / kg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 6 mg / kg at least every 12 months.

[0314] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 6 mg / kg after 3 months, a third administration of an anti-TKVU9 antibody at a dose of 6 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 6 mg / kg every 12 months.

[0315] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 6 mg / kg after 6 months, a third administration of an anti-TKVU9 antibody at a dose of 6 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 6 mg / kg every 12 months.

[0316] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 6 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a dose of 6 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 6 mg / kg every 12 months.

[0317] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 3 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 6 mg / kg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 6 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 6 mg / kg every 12 months.

[0318] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose of 3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 7 mg / kg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 7 mg / kg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 7 mg / kg at least every 12 months.

[0319] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 7 mg / kg 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 7 mg / kg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 7 mg / kg every 12 months.

[0320] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 7 mg / kg 6 months later, a third administration of an anti-TKVU9 antibody at a dose of 7 mg / kg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 7 mg / kg every 12 months.

[0321] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 7 mg / kg 9 months later, a third administration of an anti-TKVU9 antibody at a dose of 7 mg / kg 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 7 mg / kg every 12 months.

[0322] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TKVU9 antibody at a dose of 3.5 mg / kg, a second administration of the anti-TKVU9 antibody at a dose of 7 mg / kg 12 months later, a third administration of the anti-TKVU9 antibody at a dose of 7 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 7 mg / kg every 12 months.

[0323] In some embodiments of the invention, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0324] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 8 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0325] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 8 mg / kg 9 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 8 mg / kg every 9 months; or every 12 months.

[0326] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 8 mg / kg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 8 mg / kg every 12 months.

[0327] In some embodiments of the invention, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0328] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 9 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0329] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 9 mg / kg 9 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 9 mg / kg every 9 months; or every 12 months.

[0330] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 4.5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 9 mg / kg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 9 mg / kg every 12 months.

[0331] In some embodiments of the invention, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0332] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 10 mg / kg 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0333] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 10 mg / kg after 9 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 10 mg / kg every 9 months; or every 12 months.

[0334] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 10 mg / kg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 10 mg / kg every 12 months.

[0335] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 75-300 mg, a second administration of an anti-TRBV9 antibody at a basal dose of 325-675 mg at least 3 months later, a third administration of an anti-TRBV9 antibody at a basal dose of 325-675 mg at least 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a basal dose of 325-675 mg at least every 12 months.

[0336] In some embodiments, the method comprises first administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 75-300 mg, a second administration of the anti-TRBV9 antibody at a basal dose of 325-675 mg 3 months later, a third administration of the anti-TRBV9 antibody at a basal dose of 325-675 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a basal dose of 325-675 mg every 12 months. In some embodiments, the method comprises first administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 75-300 mg, a second administration of the anti-TRBV9 antibody at a basal dose of 325-675 mg 6 months later, a third administration of the anti-TRBV9 antibody at a basal dose of 325-675 mg 6 months later; or 9 months later; or after 12 months; and subsequent administration of anti-TKVU9 antibody at a basic dose of 325-675 mg every 12 months.

[0337] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 75-300 mg, a second administration of an anti-TRBV9 antibody at a basal dose of 325-675 mg after 9 months, a third administration of an anti-TRBV9 antibody at a basal dose of 325-675 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TRBV9 antibody at a basal dose of 325-675 mg every 12 months.

[0338] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 75-300 mg, a second administration of an anti-TRBV9 antibody at a basal dose of 325-675 mg 12 months later, a third administration of an anti-TRBV9 antibody at a basal dose of 325-675 mg 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a basal dose of 325-675 mg every 12 months.

[0339] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 100-275 mg, a second administration of an anti-TRBV9 antibody at a basal dose of 350-650 mg at least 3 months later, a third administration of an anti-TRBV9 antibody at a basal dose of 350-650 mg at least 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a basal dose of 350-650 mg at least every 12 months.

[0340] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 100-275 mg, a second administration of the anti-TKVU9 antibody at a basal dose of 350-650 mg after 3 months, a third administration of the anti-TKVU9 antibody at a basal dose of 350-650 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a basal dose of 350-650 mg every 12 months.

[0341] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 100-275 mg, a second administration of an anti-TRBV9 antibody at a basal dose of 350-650 mg 6 months later, a third administration of an anti-TRBV9 antibody at a basal dose of 350-650 mg 6 months later; or 9 months later; or 12 months; and subsequent administrations of an anti-TRBV9 antibody at a basal dose of 350-650 mg every 12 months.

[0342] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 100-275 mg, a second administration of an anti-TRBV9 antibody at a basal dose of 350-650 mg after 9 months, a third administration of an anti-TRBV9 antibody at a basal dose of 350-650 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TRBV9 antibody at a basal dose of 350-650 mg every 12 months.

[0343] In some embodiments, the method comprises a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 100-275 mg, a second administration of an anti-TRBV9 antibody at a basal dose of 350-650 mg 12 months later, a third administration of an anti-TRBV9 antibody at a basal dose of 350-650 mg 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a basal dose of 350-650 mg every 12 months.

[0344] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment of a T cell receptor, comprising a first administration to a subject in need thereof of an anti-TBV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of the anti-TBV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least 3 months later, a third administration of the anti-TBV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least 6 months later, and subsequent administrations of the anti-TBV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least every 12 months.

[0345] In some embodiments, the method comprises (i) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 3 months later, a third administration of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 6 months later, and subsequent administrations of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months, or

[0346] (j) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 3 months later, a third administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months, or

[0347] (iii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 3 months later, a third administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 12 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months, or

[0348] (iv) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 6 months later, a third administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 6 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months, or

[0349] (u) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 6 months later, a third administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months, or

[0350] (vi) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 6 months later, a third administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 12 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months, or

[0351] (vii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 9 months later, a third administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months, or

[0352] (viii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 9 months later, a third administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 12 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months, or

[0353] (1x) the first administration to a subject in need thereof of anti-TKVU9 antibody at a dose of 100-150 mg; or 225-275 mg, the second administration of anti-TKVU9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg after 12 months, the third administration of anti-TKVU9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg after 12 months and subsequent administrations of anti-TKVU9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months.

[0354] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in their T cell receptor, comprising a first administration to a subject in need thereof of an anti-TBV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of the anti-TBV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least 3 months later, a third administration of the anti-TBV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least 6 months later, and subsequent administrations of the anti-TBV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least every 12 months.

[0355] In some embodiments, the method comprises (i) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 3 months later, a third administration of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 6 months later, and subsequent administrations of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months, or

[0356] (j) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 3 months later, a third administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months, or

[0357] (iii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 3 months later, a third administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 12 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months, or

[0358] (iv) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 6 months later, a third administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 6 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months, or

[0359] (u) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 6 months later, a third administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months, or

[0360] (vi) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 6 months later, a third administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 12 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months, or

[0361] (vii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 9 months later, a third administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months, or

[0362] (viii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 9 months later, a third administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 12 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months, or

[0363] (1x) the first administration to a subject in need thereof of anti-TKVU9 antibody at a dose of 115-135 mg; or 240-260 mg, the second administration of anti-TKVU9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg after 12 months, the third administration of anti-TKVU9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg after 12 months and subsequent administrations of anti-TKVU9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months.

[0364] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment of a T cell receptor, comprising first administering to a subject in need thereof an anti-TBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of the anti-TBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 3 months later, a third administration of the anti-TBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 6 months later and subsequent administrations of anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least every 12 months.

[0365] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment of a T cell receptor, comprising (i) a first administration to a subject in need thereof of an anti-TBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of the anti-TBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 3 months later, a third administration of the anti-TBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 6 months and subsequent administrations of anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0366] (j) the first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, the second administration of an anti-TKVU9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 3 months later, the third administration of an anti-TKVU9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 9 months and subsequent administrations of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0367] (iii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 3 months later, a third administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 12 months and subsequent administrations of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0368] (iv) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 6 months later, a third administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 6 months and subsequent administrations of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0369] (y) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 6 months later, a third administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 9 months and subsequent administrations of anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or (vi) a first administration to a subject in need thereof of anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg;or 630 mg at 6 months, a third administration of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at 12 months, and subsequent administrations of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or;

[0370] (vii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 9 months later, a third administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 9 months and subsequent administrations of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0371] (viii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 9 months later, a third administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 12 months and subsequent administrations of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0372] (ix) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 12 months later, a third administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 12 months and subsequent administrations of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months.

[0373] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 370 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg at least every 12 months.

[0374] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 370 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 12 months.

[0375] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg after 6 months; a third administration of an anti-TKVU9 antibody at a dose of 370 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 12 months.

[0376] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 370 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 12 months.

[0377] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 370 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 12 months.

[0378] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 375 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg at least every 12 months.

[0379] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 375 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 12 months.

[0380] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg after 6 months; a third administration of an anti-TKVU9 antibody at a dose of 375 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 12 months.

[0381] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 375 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 12 months.

[0382] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 375 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 12 months.

[0383] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 380 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg at least every 12 months.

[0384] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 380 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 12 months.

[0385] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg after 6 months; a third administration of an anti-TKVU9 antibody at a dose of 380 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 12 months.

[0386] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 380 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 12 months.

[0387] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 380 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 12 months.

[0388] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 370 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg at least every 12 months when the subject weighs between 30 and 50 kg.

[0389] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 370 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 12 months when the subject weighs from 30 to 50 kg.

[0390] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg 6 months later; a third administration of an anti-TKVU9 antibody at a dose of 370 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 12 months when the subject weighs between 30 and 50 kg.

[0391] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 370 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 12 months when the subject weighs from 30 to 50 kg.

[0392] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 120 mg, a second administration of an anti-TKVU9 antibody at a dose of 370 mg 12 months later, a third administration of an anti-TKVU9 antibody at a dose of 370 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 370 mg every 12 months when the subject weighs between 30 and 50 kg.

[0393] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 375 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg at least every 12 months when the subject weighs between 30 and 50 kg.

[0394] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 375 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 12 months when the subject weighs from 30 to 50 kg.

[0395] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg 6 months later; a third administration of an anti-TKVU9 antibody at a dose of 375 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 12 months when the subject weighs between 30 and 50 kg.

[0396] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 375 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 12 months when the subject weighs from 30 to 50 kg.

[0397] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 125 mg, a second administration of an anti-TKVU9 antibody at a dose of 375 mg 12 months later, a third administration of an anti-TKVU9 antibody at a dose of 375 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 375 mg every 12 months when the subject weighs between 30 and 50 kg.

[0398] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 380 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg at least every 12 months when the subject weighs between 30 and 50 kg.

[0399] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 380 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 12 months when the subject weighs from 30 to 50 kg.

[0400] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg after 6 months; a third administration of an anti-TKVU9 antibody at a dose of 380 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 12 months when the subject weighs from 30 to 50 kg.

[0401] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 380 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 12 months when the subject weighs from 30 to 50 kg.

[0402] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 130 mg, a second administration of an anti-TKVU9 antibody at a dose of 380 mg 12 months later, a third administration of an anti-TKVU9 antibody at a dose of 380 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 380 mg every 12 months when the subject weighs between 30 and 50 kg.

[0403] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 495 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg at least every 12 months.

[0404] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 495 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 12 months.

[0405] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg after 6 months; a third administration of an anti-TKVU9 antibody at a dose of 495 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 12 months.

[0406] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 495 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 12 months.

[0407] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 495 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 12 months.

[0408] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 500 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg at least every 12 months.

[0409] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 500 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 12 months.

[0410] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg after 6 months; a third administration of an anti-TKVU9 antibody at a dose of 500 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 12 months.

[0411] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 500 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 12 months.

[0412] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 500 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 12 months.

[0413] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 505 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg at least every 12 months.

[0414] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 505 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 12 months.

[0415] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg after 6 months; a third administration of an anti-TKVU9 antibody at a dose of 505 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 12 months.

[0416] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 505 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 12 months.

[0417] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 505 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 12 months.

[0418] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 495 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg at least every 12 months when the subject weighs between 51 and 89 kg.

[0419] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 495 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 12 months when the subject weighs from 51 to 89 kg.

[0420] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg 6 months later; a third administration of an anti-TKVU9 antibody at a dose of 495 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 12 months when the subject weighs between 51 and 89 kg.

[0421] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 495 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 12 months when the subject weighs from 51 to 89 kg.

[0422] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 495 mg 12 months later, a third administration of an anti-TKVU9 antibody at a dose of 495 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 495 mg every 12 months when the subject weighs between 51 and 89 kg.

[0423] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 500 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg at least every 12 months when the subject weighs between 51 and 89 kg.

[0424] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 500 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 12 months when the subject weighs from 51 to 89 kg.

[0425] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg 6 months later; a third administration of an anti-TKVU9 antibody at a dose of 500 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 12 months when the subject weighs between 51 and 89 kg.

[0426] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 500 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 12 months when the subject weighs from 51 to 89 kg.

[0427] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 500 mg 12 months later, a third administration of an anti-TKVU9 antibody at a dose of 500 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 500 mg every 12 months when the subject weighs between 51 and 89 kg.

[0428] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 505 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg at least every 12 months when the subject weighs between 51 and 89 kg.

[0429] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 505 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 12 months when the subject weighs from 51 to 89 kg.

[0430] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg 6 months later; a third administration of an anti-TKVU9 antibody at a dose of 505 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 12 months when the subject weighs between 51 and 89 kg.

[0431] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 505 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 12 months when the subject weighs from 51 to 89 kg.

[0432] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 505 mg 12 months later, a third administration of an anti-TKVU9 antibody at a dose of 505 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 505 mg every 12 months when the subject weighs between 51 and 89 kg.

[0433] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 620 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg at least every 12 months.

[0434] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 620 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 12 months.

[0435] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg after 6 months; a third administration of an anti-TKVU9 antibody at a dose of 620 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 12 months.

[0436] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 620 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 12 months.

[0437] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 620 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 12 months.

[0438] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 625 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg at least every 12 months.

[0439] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 625 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 12 months.

[0440] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg after 6 months; a third administration of an anti-TKVU9 antibody at a dose of 625 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 12 months.

[0441] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 625 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 12 months.

[0442] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 625 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 12 months.

[0443] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 630 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg at least every 12 months.

[0444] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 630 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 12 months.

[0445] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg after 6 months; a third administration of an anti-TKVU9 antibody at a dose of 630 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 12 months.

[0446] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 630 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 12 months.

[0447] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg after 12 months, a third administration of an anti-TKVU9 antibody at a dose of 630 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 12 months.

[0448] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 620 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg at least every 12 months when the subject weighs between 90 and 150 kg.

[0449] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 620 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 12 months when the subject weighs from 90 to 150 kg.

[0450] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg 6 months later; a third administration of an anti-TKVU9 antibody at a dose of 620 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 12 months when the subject weighs between 90 and 150 kg.

[0451] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 620 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 12 months when the subject weighs from 90 to 150 kg.

[0452] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 245 mg, a second administration of an anti-TKVU9 antibody at a dose of 620 mg 12 months later, a third administration of an anti-TKVU9 antibody at a dose of 620 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 620 mg every 12 months when the subject weighs between 90 and 150 kg.

[0453] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 625 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg at least every 12 months when the subject weighs between 90 and 150 kg.

[0454] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 625 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 12 months when the subject weighs from 90 to 150 kg.

[0455] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg 6 months later; a third administration of an anti-TKVU9 antibody at a dose of 625 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 12 months when the subject weighs between 90 and 150 kg.

[0456] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 625 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 12 months when the subject weighs from 90 to 150 kg.

[0457] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 250 mg, a second administration of an anti-TKVU9 antibody at a dose of 625 mg 12 months later, a third administration of an anti-TKVU9 antibody at a dose of 625 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 625 mg every 12 months when the subject weighs between 90 and 150 kg.

[0458] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg at least 3 months later, a third administration of an anti-TKVU9 antibody at a dose of 630 mg at least 6 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg at least every 12 months when the subject weighs between 90 and 150 kg.

[0459] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg after 3 months; a third administration of an anti-TKVU9 antibody at a dose of 630 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 12 months when the subject weighs from 90 to 150 kg.

[0460] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg 6 months later; a third administration of an anti-TKVU9 antibody at a dose of 630 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 12 months when the subject weighs between 90 and 150 kg.

[0461] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg after 9 months; a third administration of an anti-TKVU9 antibody at a dose of 630 mg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 12 months when the subject weighs from 90 to 150 kg.

[0462] In some embodiments, the method comprises a first administration of an anti-TKVU9 antibody at a dose of 255 mg, a second administration of an anti-TKVU9 antibody at a dose of 630 mg 12 months later, a third administration of an anti-TKVU9 antibody at a dose of 630 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 630 mg every 12 months when the subject weighs between 90 and 150 kg.

[0463] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the anti-TKVV9 antibody is administered to a subject in need thereof at a dose of 0.03-10 mg / kg.

[0464] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the anti-TKVV9 antibody is administered to a subject in need thereof at a dose of 0.03-7 mg / kg.

[0465] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the anti-TKVV9 antibody is administered to a subject in need thereof at a dose of 0.3-10 mg / kg.

[0466] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the anti-TKVV9 antibody is administered to a subject in need thereof at a dose of 0.3-7 mg / kg.

[0467] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the anti-TKVV9 antibody is administered to a subject in need thereof at a dose of 1-7 mg / kg.

[0468] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 2-7 mg / kg.

[0469] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 3-7 mg / kg.

[0470] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 4-7 mg / kg.

[0471] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 5-7 mg / kg.

[0472] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 6-7 mg / kg.

[0473] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 1 mg / kg, or 2 mg / kg, or 3 mg / kg, or 4 mg / kg, or 5 mg / kg, or 6 mg / kg, or 7 mg / kg.

[0474] In some embodiments, the anti-TKVU9 antibody is administered at a dose of 7.5 mg / kg, or 8 mg / kg, or 8.5 mg / kg, or 9 mg / kg, or 9.5 mg / kg, or 10 mg / kg.

[0475] In some embodiments, the anti-TKV9 antibody is administered at least every 3 to 12 months.

[0476] In some embodiments, the anti-TKV9 antibody is administered every 3 to 12 months.

[0477] In some embodiments, the anti-TKV9 antibody is administered at least every 6 to 12 months.

[0478] In some embodiments, the anti-TKVU9 antibody is administered every 6 to 12 months.

[0479] In some embodiments, the anti-TKV9 antibody is administered at least every 3 months; or at least every 6 months; or at least every 9 months; or at least every 12 months.

[0480] In some embodiments, the anti-TKV9 antibody is administered every 3 months; or every 6 months; or every 9 months; or every 12 months.

[0481] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the anti-TKVV9 antibody is administered to a subject in need thereof at a dose of 75-675 mg.

[0482] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the anti-TKVV9 antibody is administered to a subject in need thereof at a dose of 100-650 mg.

[0483] In one aspect, the present invention relates to the use of an anti-TKV9 antibody for treating a disease or disorder mediated by T lymphocytes bearing the TRBV9 segment of a T cell receptor, wherein the anti-TKV9 antibody is administered to a subject in need thereof at a dose of 75-175 mg; or 200-300 mg; or 325-425 mg; or 450-650 mg; or 575-675 mg. In one aspect, the present invention relates to the use of an anti-TKV9 antibody for treating a disease or disorder mediated by T lymphocytes bearing the TRBV9 segment of a T cell receptor, wherein the anti-TKV9 antibody is administered to a subject in need thereof at a dose of 100-150 mg; or 225-275 mg; or 350-400 mg; or 475-525 mg; or 600-650 mg.

[0484] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the anti-TKVV9 antibody is administered to a subject in need thereof at a dose of 115-135 mg; or 240-260 mg; or 365-385 mg; or 490-510 mg; or 615-635 mg.

[0485] In some embodiments, the anti-TKV9 antibody is administered at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

[0486] In some embodiments, the anti-TKV9 antibody is administered at least every 3 to 12 months.

[0487] In some embodiments, the anti-TKV9 antibody is administered every 3 to 12 months.

[0488] In some embodiments, the anti-TKV9 antibody is administered at least every 6 to 12 months.

[0489] In some embodiments, the anti-TKVU9 antibody is administered every 6 to 12 months.

[0490] In some embodiments, the anti-TKV9 antibody is administered at least every 3 months; or at least every 6 months; or at least every 9 months; or at least every 12 months.

[0491] In some embodiments, the anti-TKV9 antibody is administered every 3 months; or every 6 months; or every 9 months; or every 12 months.

[0492] In one aspect, the present invention relates to the use of an anti-TKVU9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration of the anti-TKVU9 antibody to a subject in need thereof is carried out at a dose equal to half the basic dose, 0.015-5 mg / kg, the second administration of the anti-TKVU9 antibody is carried out at a basic dose of 0.03-10 mg / kg at least 3 months later, and subsequent administrations of the anti-TIVU9 antibody are carried out at a basic dose of 0.03-10 mg / kg at least every 6 months.

[0493] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 3 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0494] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.03-10 mg / kg 6 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.03-10 mg / kg every 6 months; or every 9 months; or every 12 months. In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.03-10 mg / kg 9 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.03-10 mg / kg every 9 months; or every 12 months.

[0495] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 12 months.

[0496] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration of the anti-TKVV9 antibody to a subject in need thereof is carried out at a dose equal to half the basic dose, 0.015-3.5 mg / kg, the second administration of the anti-TKVV9 antibody is carried out at a basic dose of 0.03-7 mg / kg at least 3 months later, and subsequent administrations of the anti-TKVV9 antibody are carried out at a basic dose of 0.03-7 mg / kg at least every 6 months.

[0497] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 3 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0498] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 6 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0499] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 9 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 9 months; or every 12 months.

[0500] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg every 12 months.

[0501] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration of the anti-TKVV9 antibody to a subject in need thereof is carried out at a dose equal to half the basic dose, 0.15-5 mg / kg, the second administration of the anti-TKVV9 antibody is carried out at a basic dose of 0.3-10 mg / kg at least 3 months later, and subsequent administrations of the anti-TKVV9 antibody are carried out at a basic dose of 0.3-10 mg / kg at least every 6 months.

[0502] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg 3 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg every 6 months; or every 9 months; or every 12 months. In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of the anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg 6 months later, and subsequent administrations of the anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg every 6 months; or every 9 months; or every 12 months.In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 9 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg every 9 months; or every 12 months.

[0503] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg every 12 months.

[0504] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration of the anti-TKVV9 antibody to a subject in need thereof is carried out at a dose equal to half the basic dose, 0.15-3.5 mg / kg, the second administration of the anti-TKVV9 antibody is carried out at a basic dose of 0.3-7 mg / kg at least 3 months later, and subsequent administrations of the anti-TKVV9 antibody are carried out at a basic dose of 0.3-7 mg / kg at least every 6 months.

[0505] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose equal to half the basic dose, 0.15-3.5 mg / kg, a second administration of the anti-TRBV9 antibody at a basic dose of 0.3-7 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a basic dose of 0.3-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0506] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose equal to half the basic dose, 0.15-3.5 mg / kg, a second administration of the anti-TRBV9 antibody at a basic dose of 0.3-7 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a basic dose of 0.3-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0507] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose equal to half the basic dose, 0.15-3.5 mg / kg, a second administration of the anti-TRBV9 antibody at a basic dose of 0.3-7 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a basic dose of 0.3-7 mg / kg every 9 months; or every 12 months.

[0508] In some embodiments of the invention, the use comprises the first administration to a subject in need thereof of the anti-TRBV9 antibody at a dose equal to half the basic dose, 0.15-3.5 mg / kg, the second administration of the anti-TRBV9 antibody at a basic dose of 0.3-7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a basic dose of 0.3-7 mg / kg every 12 months.

[0509] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration of the anti-TKVV9 antibody to a subject in need thereof is carried out at a dose equal to half the primary dose, 0.5-3.5 mg / kg, the second administration of the anti-TKVV9 antibody is carried out at a primary dose of 1-7 mg / kg at least 3 months later, and subsequent administrations of the anti-TKVV9 antibody are carried out at a primary dose of 1-7 mg / kg at least every 6 months.

[0510] In some embodiments, the invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in the T cell receptor, wherein the first administration to a subject in need thereof of the anti-TRBV9 antibody is carried out at a dose equal to half the basic dose, 0.5-3.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a basic dose of 1-7 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody are carried out at a basic dose of 1-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0511] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 6 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0512] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 9 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 9 months; or every 12 months.

[0513] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0514] In some embodiments, the first administration of the anti-TRBV9 antibody is at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 1 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are at a dose of 1 mg / kg at least every 6 months.

[0515] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 0.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 1 mg / kg 3 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 1 mg / kg every 6 months; or every 9 months; or every 12 months.

[0516] In some embodiments, the first administration of the anti-TKVU9 antibody is 0.5 mg / kg, the second administration of the anti-TKVU9 antibody is 1 mg / kg 6 months later, and subsequent administrations of the anti-TKVU9 antibody are 1 mg / kg every 6 months; or every 9 months; or every 12 months.

[0517] In some embodiments, the first administration of the anti-TKVU9 antibody is 0.5 mg / kg, the second administration of the anti-TKVU9 antibody is 1 mg / kg 9 months later, and subsequent administrations of the anti-TKVU9 antibody are 1 mg / kg every 9 months; or every 12 months.

[0518] In some embodiments, the first administration of the anti-TKVU9 antibody is 0.5 mg / kg, the second administration of the anti-TKVU9 antibody is 1 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody are 1 mg / kg every 12 months.

[0519] In some embodiments, the first administration of the anti-TRBV9 antibody is at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 2 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are at a dose of 2 mg / kg at least every 6 months.

[0520] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 1 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 2 mg / kg 3 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 2 mg / kg every 6 months; or every 9 months; or every 12 months.

[0521] In some embodiments, the first administration of the anti-TKVU9 antibody is 1 mg / kg, the second administration of the anti-TKVU9 antibody is 2 mg / kg 6 months later, and subsequent administrations of the anti-TKVU9 antibody are 2 mg / kg every 6 months; or every 9 months; or every 12 months.

[0522] In some embodiments, the first administration of the anti-TKVU9 antibody is 1 mg / kg, the second administration of the anti-TKVU9 antibody is 2 mg / kg 9 months later, and subsequent administrations of the anti-TKVU9 antibody are 2 mg / kg every 9 months; or every 12 months.

[0523] In some embodiments, the first administration of the anti-TKVU9 antibody is 1 mg / kg, the second administration of the anti-TKVU9 antibody is 2 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody are 2 mg / kg every 12 months.

[0524] In some embodiments, the first administration of the anti-TRBV9 antibody is at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 3 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are at a dose of 3 mg / kg at least every 6 months.

[0525] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 1.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 3 mg / kg 3 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 3 mg / kg every 6 months; or every 9 months; or every 12 months.

[0526] In some embodiments, the first administration of the anti-TKVU9 antibody is 1.5 mg / kg, the second administration of the anti-TKVU9 antibody is 3 mg / kg 6 months later, and subsequent administrations of the anti-TKVU9 antibody are 3 mg / kg every 6 months; or every 9 months; or every 12 months.

[0527] In some embodiments, the first administration of the anti-TKVU9 antibody is 1.5 mg / kg, the second administration of the anti-TKVU9 antibody is 3 mg / kg 9 months later, and subsequent administrations of the anti-TKVU9 antibody are 3 mg / kg every 9 months; or every 12 months.

[0528] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 1.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 3 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 3 mg / kg every 12 months.

[0529] In some embodiments, the first administration of the anti-TRBV9 antibody is at a dose of 2 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 4 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are at a dose of 4 mg / kg at least every 6 months.

[0530] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 2 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 4 mg / kg 3 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 4 mg / kg every 6 months; or every 9 months; or every 12 months.

[0531] In some embodiments, the first administration of the anti-TKVU9 antibody is 2 mg / kg, the second administration of the anti-TKVU9 antibody is 4 mg / kg 6 months later, and subsequent administrations of the anti-TKVU9 antibody are 4 mg / kg every 6 months; or every 9 months; or every 12 months.

[0532] In some embodiments, the first administration of the anti-TKVU9 antibody is 2 mg / kg, the second administration of the anti-TKVU9 antibody is 4 mg / kg 9 months later, and subsequent administrations of the anti-TKVU9 antibody are 4 mg / kg every 9 months; or every 12 months.

[0533] In some embodiments, the first administration of the anti-TKVU9 antibody is 2 mg / kg, the second administration of the anti-TKVU9 antibody is 4 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody are 4 mg / kg every 12 months.

[0534] In some embodiments, the first administration of the anti-TRBV9 antibody is at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 5 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are at a dose of 5 mg / kg at least every 6 months.

[0535] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 2.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 5 mg / kg 3 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 5 mg / kg every 6 months; or every 9 months; or every 12 months.

[0536] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 2.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 5 mg / kg 6 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 5 mg / kg every 6 months; or every 9 months; or every 12 months.

[0537] In some embodiments, the first administration of the anti-TKV9 antibody is 2.5 mg / kg, the second administration of the anti-TKV9 antibody is 5 mg / kg 9 months later, and subsequent administrations of the anti-TKV9 antibody are 5 mg / kg every 9 months; or every 12 months. In some embodiments, the first administration of the anti-TKV9 antibody is 2.5 mg / kg, the second administration of the anti-TKV9 antibody is 5 mg / kg 12 months later, and subsequent administrations of the anti-TKV9 antibody are 5 mg / kg every 12 months.

[0538] In some embodiments, the first administration of the anti-TRBV9 antibody is at a dose of 3 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 6 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are at a dose of 6 mg / kg at least every 6 months.

[0539] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 3 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 6 mg / kg 3 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 6 mg / kg every 6 months; or every 9 months; or every 12 months.

[0540] In some embodiments, the first administration of the anti-TKVU9 antibody is 3 mg / kg, the second administration of the anti-TKVU9 antibody is 6 mg / kg 6 months later, and subsequent administrations of the anti-TKVU9 antibody are 6 mg / kg every 6 months; or every 9 months; or every 12 months.

[0541] In some embodiments, the first administration of the anti-TKVU9 antibody is 3 mg / kg, the second administration of the anti-TKVU9 antibody is 6 mg / kg 9 months later, and subsequent administrations of the anti-TKVU9 antibody are 6 mg / kg every 9 months; or every 12 months.

[0542] In some embodiments, the first administration of the anti-TKVU9 antibody is 3 mg / kg, the second administration of the anti-TKVU9 antibody is 6 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody are 6 mg / kg every 12 months.

[0543] In some embodiments, the first administration of the anti-TRBV9 antibody is at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 7 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are at a dose of 7 mg / kg at least every 6 months.

[0544] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 3.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 7 mg / kg 3 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0545] In some embodiments, the first administration of the anti-TKVU9 antibody is 3.5 mg / kg, the second administration of the anti-TKVU9 antibody is 7 mg / kg 6 months later, and subsequent administrations of the anti-TKVU9 antibody are 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0546] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 3.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 7 mg / kg 9 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 7 mg / kg every 9 months; or every 12 months.

[0547] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 3.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 7 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 7 mg / kg every 12 months.

[0548] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 4 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 8 mg / kg 3 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0549] In some embodiments, the first administration of the anti-TKVU9 antibody is 4 mg / kg, the second administration of the anti-TKVU9 antibody is 8 mg / kg 6 months later, and subsequent administrations of the anti-TKVU9 antibody are 8 mg / kg every 6 months; or every 9 months; or every 12 months.

[0550] In some embodiments, the first administration of the anti-TKVU9 antibody is 4 mg / kg, the second administration of the anti-TKVU9 antibody is 8 mg / kg 9 months later, and subsequent administrations of the anti-TKVU9 antibody are 8 mg / kg every 9 months; or every 12 months.

[0551] In some embodiments, the first administration of the anti-TKVU9 antibody is 4 mg / kg, the second administration of the anti-TKVU9 antibody is 8 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody are 8 mg / kg every 12 months.

[0552] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 4.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 9 mg / kg 3 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0553] In some embodiments, the first administration of the anti-TKVU9 antibody is 4.5 mg / kg, the second administration of the anti-TKVU9 antibody is 9 mg / kg 6 months later, and subsequent administrations of the anti-TKVU9 antibody are 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0554] In some embodiments, the first administration of the anti-TKVU9 antibody is 4.5 mg / kg, the second administration of the anti-TKVU9 antibody is 9 mg / kg 9 months later, and subsequent administrations of the anti-TKVU9 antibody are 9 mg / kg every 9 months; or every 12 months.

[0555] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 4.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 9 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 9 mg / kg every 12 months.

[0556] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 10 mg / kg 3 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0557] In some embodiments, the first administration of the anti-TKVU9 antibody is 5 mg / kg, the second administration of the anti-TKVU9 antibody is 10 mg / kg 6 months later, and subsequent administrations of the anti-TKVU9 antibody are 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0558] In some embodiments, the first administration of the anti-TKVU9 antibody is 5 mg / kg, the second administration of the anti-TKVU9 antibody is 10 mg / kg 9 months later, and subsequent administrations of the anti-TKVU9 antibody are 10 mg / kg every 9 months; or every 12 months.

[0559] (viii)nepBoe administration of an anti-TKVU9 antibody at a dose of 5 mg / kg, a second In some embodiments, a first administration of an anti-TKVU9 antibody at a dose of 5 mg / kg, a second administration of an anti-TKVU9 antibody at a dose of 10 mg / kg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a dose of 10 mg / kg every 12 months.

[0560] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration to a subject in need thereof of the anti-TKVV9 antibody is carried out at a dose of 75-300 mg, a second administration of the anti-TKVV9 antibody at a primary dose of 325-675 mg at least 3 months later, and subsequent administrations of the anti-TKVV9 antibody at a primary dose of 325-675 mg at least every 6 months.

[0561] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 75-300 mg, a second administration of an anti-TKVU9 antibody at a primary dose of 325-675 mg after 3 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 325-675 mg every 6 months; or every 9 months; or every 12 months.

[0562] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 75-300 mg, a second administration of an anti-TKVU9 antibody at a primary dose of 325-675 mg after 6 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 325-675 mg every 6 months; or every 9 months; or every 12 months.

[0563] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 75-300 mg, a second administration of an anti-TKVU9 antibody at a primary dose of 325-675 mg after 9 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 325-675 mg every 9 months; or every 12 months.

[0564] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 75-300 mg, a second administration of an anti-TKVU9 antibody at a primary dose of 325-675 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 325-675 mg every 12 months.

[0565] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration to a subject in need thereof of the anti-TKVV9 antibody is carried out at a dose of 100-275 mg, a second administration of the anti-TKVV9 antibody at a primary dose of 350-650 mg at least 3 months later, and subsequent administrations of the anti-TKVV9 antibody at a primary dose of 350-650 mg at least every 6 months.

[0566] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 100-275 mg, a second administration of an anti-TKVU9 antibody at a primary dose of 350-650 mg after 3 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 350-650 mg every 6 months; or every 9 months; or every 12 months.

[0567] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-275 mg, a second administration of the anti-TKV9 antibody at a basal dose of 350-650 mg 6 months later, and subsequent administrations of the anti-TKV9 antibody at a basal dose of 350-650 mg every 6 months; or every 9 months; or every 12 months. In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-275 mg, a second administration of the anti-TKV9 antibody at a basal dose of 350-650 mg 9 months later, and subsequent administrations of the anti-TKV9 antibody at a basal dose of 350-650 mg every 9 months; or every 12 months.

[0568] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 100-275 mg, a second administration of an anti-TKVU9 antibody at a primary dose of 350-650 mg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 350-650 mg every 12 months.

[0569] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration to a subject in need thereof of the anti-TRBV9 antibody is carried out at a dose of 100-150 mg; or 225-275 mg, the second administration of the anti-TRBV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least every 6 months.

[0570] In some embodiments, the use comprises (i) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 3 months later and subsequent administrations of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 6 months; or (j) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg after 3 months and subsequent administration of anti-TKVU9 antibody at a basic dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 9 months; or

[0571] (iii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 3 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months; or

[0572] (iv) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 6 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 6 months; or

[0573] (u) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 6 months later and subsequent administrations of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 9 months; or (vi) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of the anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg after 6 months and subsequent administrations of anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months; or (vii) a first administration to a subject in need thereof of anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg after 9 months and subsequent administrations of anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg;or 600-650 mg every 9 months; or;

[0574] (viii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months; or

[0575] (ix) a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TKVU9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg 12 months later, and subsequent administrations of an anti-TKVU9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg every 12 months.

[0576] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration to a subject in need thereof of the anti-TRBV9 antibody is carried out at a dose of 115-135 mg; or 240-260 mg, the second administration of the anti-TRBV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least every 6 months.

[0577] In some embodiments, the use comprises (i) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 3 months later and subsequent administrations of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 6 months; or (j) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg after 3 months and subsequent administrations of anti-TKVU9 antibody at a basic dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 9 months; or

[0578] (iii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 3 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months; or

[0579] (iv) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 6 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 6 months; or

[0580] (u) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 6 months later and subsequent administrations of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 9 months; or (vi) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of the anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg after 6 months and subsequent administrations of anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months; or

[0581] (vii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 9 months; or

[0582] (viii) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 9 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months; or

[0583] (ix) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg 12 months later, and subsequent administrations of an anti-TKV9 antibody at a basal dose of 365-385 mg; or 490-510 mg; or 615-635 mg every 12 months.

[0584] In one aspect, the present invention relates to the use of an anti-TKV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in their T cell receptor, wherein a first administration to a subject in need thereof of the anti-TKV9 antibody is carried out at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of the anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 3 months later, and subsequent administrations of the anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least every 6 months.

[0585] In some embodiments, the invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment of a T cell receptor, wherein (i) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of the anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 6 months; or (j) a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TKV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg;or 620 mg; or 625 mg; or 630 mg after 3 months and subsequent administrations of anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 9 months; or (iii) a first administration to a subject in need thereof of anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 3 months and subsequent administrations of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months; or;

[0586] (iv) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 6 months; or

[0587] (y) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 9 months; or

[0588] (vi) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months; or

[0589] (vii) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 9 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 9 months; or

[0590] (viii) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 9 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months; or

[0591] (ix) a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 12 months later, and subsequent administrations of an anti-TRBV9 antibody at a priming dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months.

[0592] In some embodiments, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 370 mg at least every 6 months. In some embodiments, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 370 mg at least every 6 months.

[0593] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg after 3 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months.

[0594] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg after 6 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months.

[0595] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg after 9 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 370 mg every 9 months; or every 12 months.

[0596] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 370 mg every 12 months.

[0597] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 125 mg, a second administration of the anti-TKVU9 antibody at a dose of 375 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 375 mg at least every 6 months.

[0598] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 125 mg, a second administration of the anti-TKVU9 antibody at a dose of 375 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months.

[0599] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 125 mg, a second administration of the anti-TKVU9 antibody at a dose of 375 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months.

[0600] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 125 mg, a second administration of the anti-TKVU9 antibody at a dose of 375 mg after 9 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 375 mg every 9 months; or every 12 months.

[0601] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 125 mg, a second administration of the anti-TKVU9 antibody at a dose of 375 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 375 mg every 12 months.

[0602] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 130 mg, a second administration of the anti-TKVU9 antibody at a dose of 380 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 380 mg at least every 6 months.

[0603] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 130 mg, a second administration of the anti-TKVU9 antibody at a dose of 380 mg after 3 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0604] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 130 mg, a second administration of the anti-TKVU9 antibody at a dose of 380 mg after 6 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0605] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 130 mg, a second administration of the anti-TKVU9 antibody at a dose of 380 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 380 mg every 9 months; or every 12 months.

[0606] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 130 mg, a second administration of the anti-TKVU9 antibody at a dose of 380 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 380 mg every 12 months.

[0607] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 370 mg at least every 6 months when the subject weighs 30 to 50 kg.

[0608] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0609] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0610] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 370 mg every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0611] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 120 mg, a second administration of the anti-TKVU9 antibody at a dose of 370 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 370 mg every 12 months when the subject weighs from 30 to 50 kg.

[0612] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 125 mg, a second administration of the anti-TKVU9 antibody at a dose of 375 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 375 mg at least every 6 months when the subject weighs 30 to 50 kg.

[0613] In some embodiments, the administration comprises a first administration of the anti-TKVY9 antibody at a dose of 125 mg, a second administration of the anti-TKVY9 antibody at a dose of 375 mg 3 months later; and subsequent administrations of the anti-TKVY9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months when the subject weighs from 30 to 50 kg. In some embodiments, the administration comprises a first administration of the anti-TKVY9 antibody at a dose of 125 mg, a second administration of the anti-TKVY9 antibody at a dose of 375 mg 6 months later; and subsequent administrations of the anti-TKVY9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months when the subject weighs from 30 to 50 kg.

[0614] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 125 mg, a second administration of the anti-TKVU9 antibody at a dose of 375 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 375 mg every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0615] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 125 mg, a second administration of the anti-TKVU9 antibody at a dose of 375 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 375 mg every 12 months when the subject weighs from 30 to 50 kg.

[0616] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 130 mg, a second administration of the anti-TKVU9 antibody at a dose of 380 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 380 mg at least every 6 months when the subject weighs 30 to 50 kg.

[0617] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 130 mg, a second administration of the anti-TKVU9 antibody at a dose of 380 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0618] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 130 mg, a second administration of the anti-TKVU9 antibody at a dose of 380 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0619] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 130 mg, a second administration of the anti-TKVU9 antibody at a dose of 380 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 380 mg every 9 months; or every 12 months when the subject weighs between 30 and 50 kg.

[0620] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 130 mg, a second administration of the anti-TKVU9 antibody at a dose of 380 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 380 mg every 12 months when the subject weighs 30 to 50 kg.

[0621] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 495 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 495 mg at least every 6 months.

[0622] In some embodiments, the administration comprises a first administration of the anti-TKV9 antibody at a dose of 245 mg, a second administration of the anti-TKV9 antibody at a dose of 495 mg 3 months later; and subsequent administrations of the anti-TKV9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months. In some embodiments, the administration comprises a first administration of the anti-TKV9 antibody at a dose of 245 mg, a second administration of the anti-TKV9 antibody at a dose of 495 mg 6 months later; and subsequent administrations of the anti-TKV9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months.

[0623] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 495 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 495 mg every 9 months; or every 12 months.

[0624] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 495 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 495 mg every 12 months.

[0625] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 500 mg at least every 6 months.

[0626] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg after 3 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 500 mg every 6 months; or every 9 months; or every 12 months.

[0627] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 500 mg every 6 months; or every 9 months; or every 12 months.

[0628] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg after 9 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 500 mg every 9 months; or every 12 months.

[0629] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 500 mg every 12 months.

[0630] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 505 mg at least every 6 months.

[0631] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months.

[0632] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months.

[0633] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 505 mg every 9 months; or every 12 months.

[0634] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 505 mg every 12 months.

[0635] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 495 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 495 mg at least every 6 months when the subject weighs from 51 to 89 kg.

[0636] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 495 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months when the subject weighs from 51 to 89 kg.

[0637] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 495 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months when the subject weighs from 51 to 89 kg.

[0638] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 495 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 495 mg every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0639] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 495 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 495 mg every 12 months when the subject weighs from 51 to 89 kg.

[0640] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 500 mg at least every 6 months when the subject weighs from 51 to 89 kg.

[0641] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 500 mg every 6 months; or every 9 months; or every 12 months when the subject weighs from 51 to 89 kg.

[0642] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 500 mg every 6 months; or every 9 months; or every 12 months when the subject weighs from 51 to 89 kg.

[0643] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 500 mg every 9 months; or every 12 months when the subject's body weight is from 51 to 89 kg.

[0644] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 500 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 500 mg every 12 months when the subject weighs from 51 to 89 kg.

[0645] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 505 mg at least every 6 months when the subject weighs from 51 to 89 kg.

[0646] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0647] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 51 and 89 kg.

[0648] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 505 mg every 9 months; or every 12 months when the subject's body weight is from 51 to 89 kg.

[0649] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 505 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 505 mg every 12 months when the subject weighs from 51 to 89 kg.

[0650] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 620 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 620 mg at least every 6 months.

[0651] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 620 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months.

[0652] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 620 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months.

[0653] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 620 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 620 mg every 9 months; or every 12 months. In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 620 mg 12 months later, and subsequent administrations of the anti-TKVU9 antibody at 620 mg every 12 months.

[0654] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 625 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 625 mg at least every 6 months.

[0655] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 625 mg after 3 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0656] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 625 mg after 6 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0657] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 625 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 625 mg every 9 months; or every 12 months.

[0658] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 625 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 625 mg every 12 months.

[0659] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 630 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 630 mg at least every 6 months.

[0660] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 630 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months.

[0661] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 630 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months.

[0662] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 630 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 630 mg every 9 months; or every 12 months.

[0663] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 630 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 630 mg every 12 months.

[0664] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 620 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 620 mg at least every 6 months when the subject weighs from 90 to 150 kg.

[0665] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 620 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0666] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 620 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0667] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 620 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 620 mg every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0668] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 245 mg, a second administration of the anti-TKVU9 antibody at a dose of 620 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 620 mg every 12 months when the subject weighs from 90 to 150 kg.

[0669] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 625 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 625 mg at least every 6 months when the subject weighs from 90 to 150 kg.

[0670] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 625 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0671] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 625 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0672] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 625 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 625 mg every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0673] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 250 mg, a second administration of the anti-TKVU9 antibody at a dose of 625 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 625 mg every 12 months when the subject weighs from 90 to 150 kg.

[0674] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 630 mg at least 3 months later, and subsequent administrations of the anti-TKVU9 antibody at a dose of 630 mg at least every 6 months when the subject weighs from 90 to 150 kg.

[0675] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 630 mg 3 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0676] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 630 mg 6 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0677] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 630 mg 9 months later; and subsequent administrations of the anti-TKVU9 antibody at a dose of 630 mg every 9 months; or every 12 months when the subject weighs between 90 and 150 kg.

[0678] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 255 mg, a second administration of the anti-TKVU9 antibody at a dose of 630 mg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at 630 mg every 12 months when the subject weighs from 90 to 150 kg.

[0679] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration of the anti-TKVV9 antibody to a subject in need thereof is carried out at a dose equal to half the basic dose, 0.015-5 mg / kg, the second administration of the anti-TKVV9 antibody is carried out at a basic dose of 0.03-10 mg / kg at least 3 months later, the third administration of the anti-TKVV9 antibody is carried out at a basic dose of 0.03-10 mg / kg at least 6 months later, and subsequent administrations of the anti-TKVV9 antibody are carried out at a basic dose of 1-10 mg / kg at least every 12 months.

[0680] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 3 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 12 months.

[0681] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 6 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 12 months.

[0682] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 12 months.

[0683] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 12 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.03-10 mg / kg every 12 months.

[0684] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration of the anti-TKVV9 antibody to a subject in need thereof is carried out at a dose equal to half the primary dose, 0.015-3.5 mg / kg, the second administration of the anti-TKVV9 antibody is carried out at a primary dose of 0.03-7 mg / kg at least 3 months later, the third administration of the anti-TKVV9 antibody is carried out at a primary dose of 0.03-7 mg / kg at least 6 months later, and subsequent administrations of the anti-TKVV9 antibody are carried out at a primary dose of 1-7 mg / kg at least every 12 months.

[0685] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 3 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0686] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 6 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0687] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0688] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.015-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 12 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.03-7 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0689] In one aspect, the present invention relates to the use of an anti-TKV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, comprising a first administration to a subject in need thereof of an anti-TKV9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of an anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg at least 3 months later, a third administration of an anti-TKV9 antibody at a primary dose of 0.3-7 mg / kg at least 6 months later, and subsequent administrations of an anti-TKV9 antibody at a primary dose of 0.3-10 mg / kg at least every 12 months.

[0690] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of an anti-TRBV9 antibody at a primary dose of 0.3-10 mg / kg after 3 months, a third administration of an anti-TRBV9 antibody at a primary dose of 0.3-10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TRBV9 antibody at a primary dose of 0.3-10 mg / kg every 12 months.

[0691] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 6 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg every 12 months.

[0692] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg every 12 months.

[0693] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.15-5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 12 months, a third administration of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 0.3-10 mg / kg every 12 months.

[0694] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration of the anti-TKVV9 antibody to a subject in need thereof is carried out at a dose equal to half the basic dose, 0.15-3.5 mg / kg, the second administration of the anti-TKVV9 antibody is carried out at a basic dose of 0.3-7 mg / kg at least 3 months later, the third administration of the anti-TKVV9 antibody is carried out at a basic dose of 0.3-7 mg / kg at least 6 months later, and subsequent administrations of the anti-TKVV9 antibody are carried out at a basic dose of 0.3-7 mg / kg at least every 12 months.

[0695] In some embodiments of the invention, the use comprises the first administration to a subject in need thereof of the anti-TKVU9 antibody at a dose equal to half the basic dose, 0.15-3.5 mg / kg, the second administration of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg after 3 months, the third administration of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg every 12 months.

[0696] In some embodiments of the invention, the use comprises the first administration to a subject in need thereof of the anti-TKVU9 antibody at a dose equal to half the basic dose, 0.15-3.5 mg / kg, the second administration of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg after 6 months, the third administration of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg every 12 months.

[0697] In some embodiments of the invention, the use comprises the first administration to a subject in need thereof of the anti-TKVU9 antibody at a dose equal to half the basic dose, 0.15-3.5 mg / kg, the second administration of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg after 9 months, the third administration of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg every 12 months.

[0698] In some embodiments of the invention, the use comprises the first administration to a subject in need thereof of the anti-TKVU9 antibody at a dose equal to half the basic dose, 0.15-3.5 mg / kg, the second administration of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg after 12 months, the third administration of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a basic dose of 0.3-7 mg / kg every 12 months.

[0699] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose equal to half the primary dose, 0.5-3.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a primary dose of 1-7 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody is carried out at a primary dose of 1-7 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at a primary dose of 1-7 mg / kg at least every 12 months.

[0700] In one aspect, the present invention relates to the use of an anti-TKVV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration of the anti-TKVV9 antibody to a subject in need thereof is carried out at a dose equal to half the primary dose, 0.5-3.5 mg / kg, the second administration of the anti-TKVV9 antibody is carried out at a primary dose of 1-7 mg / kg after 3 months, the third administration of the anti-TKVV9 antibody is carried out at a primary dose of 1-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVV9 antibody are carried out at a primary dose of 1-7 mg / kg every 12 months.

[0701] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.5-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 6 months, a third administration of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0702] In some embodiments, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.5-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 9 months, a third administration of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 9 months; or after 12 months; and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0703] In some embodiments of the invention, the use comprises a first administration to a subject in need thereof of an anti-TKVU9 antibody at a dose equal to half the primary dose, 0.5-3.5 mg / kg, a second administration of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 12 months, a third administration of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg after 12 months, and subsequent administrations of an anti-TKVU9 antibody at a primary dose of 1-7 mg / kg every 12 months.

[0704] In some embodiments, the first administration of the anti-TKVU9 antibody is carried out at a dose of 0.5 mg / kg, the second administration of the anti-TKVU9 antibody is carried out at a dose of 1 mg / kg at least 3 months later, the third administration of the anti-TKVU9 antibody is carried out at a dose of 1 mg / kg at least 6 months later, and subsequent administrations of the anti-TKVU9 antibody are carried out at a dose of 1 mg / kg at least every 12 months.

[0705] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TKVU9 antibody at a dose of 1 mg / kg after 3 months, a third administration of the anti-TKVU9 antibody at a dose of 1 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 1 mg / kg every 12 months.

[0706] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TKVU9 antibody at a dose of 1 mg / kg after 6 months, a third administration of the anti-TKVU9 antibody at a dose of 1 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 1 mg / kg every 12 months.

[0707] In some embodiments, the administration comprises a first administration of the anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TKVU9 antibody at a dose of 1 mg / kg after 9 months, a third administration of the anti-TKVU9 antibody at a dose of 1 mg / kg after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody at a dose of 1 mg / kg every 12 months.

[0708] In some embodiments of the invention, the use comprises a first administration of the anti-TKVU9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TKVU9 antibody at a dose of 1 mg / kg after 12 months, a third administration of the anti-TKVU9 antibody at a dose of 1 mg / kg after 12 months, and subsequent administrations of the anti-TKVU9 antibody at a dose of 1 mg / kg every 12 months.

[0709] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 1 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 2 mg / kg at least 3 months later, the third administration of the anti-TKVU9 antibody is at a dose of 2 mg / kg at least 6 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 2 mg / kg at least every 12 months.

[0710] In some embodiments, the first administration of the anti-TKV9 antibody is at a dose of 1 mg / kg, the second administration of the anti-TKV9 antibody is at a dose of 2 mg / kg 3 months later, the third administration of the anti-TKV9 antibody is at a dose of 2 mg / kg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TKV9 antibody are at a dose of 2 mg / kg every 12 months. In some embodiments, the first administration of the anti-TKV9 antibody is at a dose of 1 mg / kg, the second administration of the anti-TKV9 antibody is at a dose of 2 mg / kg 6 months later, the third administration of the anti-TKV9 antibody is at a dose of 2 mg / kg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TKV9 antibody at a dose of 2 mg / kg every 12 months.

[0711] In some embodiments, the first administration of the anti-TKVU9 antibody is 1 mg / kg, the second administration of the anti-TKVU9 antibody is 2 mg / kg 9 months later, the third administration of the anti-TKVU9 antibody is 2 mg / kg 9 months later; or 12 months later; and subsequent administrations of the anti-TKVU9 antibody are 2 mg / kg every 12 months.

[0712] In some embodiments, the first administration of the anti-TKVU9 antibody is 1 mg / kg, the second administration of the anti-TKVU9 antibody is 2 mg / kg 12 months later, the third administration of the anti-TKVU9 antibody is 2 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody are 2 mg / kg every 12 months.

[0713] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 1.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 3 mg / kg at least 3 months later, the third administration of the anti-TKVU9 antibody is at a dose of 3 mg / kg at least 6 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 3 mg / kg at least every 12 months.

[0714] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 1.5 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 3 mg / kg after 3 months, the third administration of the anti-TKVU9 antibody is at a dose of 3 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody are at a dose of 3 mg / kg every 12 months.

[0715] In some embodiments, the first administration of the anti-TKVU9 antibody is 1.5 mg / kg, the second administration of the anti-TKVU9 antibody is 3 mg / kg 6 months later, the third administration of the anti-TKVU9 antibody is 3 mg / kg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TKVU9 antibody are 3 mg / kg every 12 months.

[0716] In some embodiments, the first administration of the anti-TKVU9 antibody is 1.5 mg / kg, the second administration of the anti-TKVU9 antibody is 3 mg / kg 9 months later, the third administration of the anti-TKVU9 antibody is 3 mg / kg 9 months later; or 12 months later; and subsequent administrations of the anti-TKVU9 antibody are 3 mg / kg every 12 months.

[0717] In some embodiments, the first administration of the anti-TKVU9 antibody is 1.5 mg / kg, the second administration of the anti-TKVU9 antibody is 3 mg / kg 12 months later, the third administration of the anti-TKVU9 antibody is 3 mg / kg 12 months later, and subsequent administrations of the anti-TKVU9 antibody are 3 mg / kg every 12 months.

[0718] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 2 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 4 mg / kg at least 3 months later, the third administration of the anti-TKVU9 antibody is at a dose of 4 mg / kg at least 6 months later, and subsequent administrations of the anti-TKVU9 antibody are at a dose of 4 mg / kg at least every 12 months.

[0719] In some embodiments, the first administration of the anti-TKVU9 antibody is at a dose of 2 mg / kg, the second administration of the anti-TKVU9 antibody is at a dose of 4 mg / kg after 3 months, the third administration of the anti-TKVU9 antibody is at a dose of 4 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TKVU9 antibody are at a dose of 4 mg / kg every 12 months.

[0720] In some embodiments, the first administration of the anti-TKVU9 antibody is 2 mg / kg, the second administration of the anti-TKVU9 antibody is 4 mg / kg 6 months later, the third administration of the anti-TKVU9 antibody is 4 mg / kg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TKVU9 antibody are 4 mg / kg every 12 months.

[0721] In some embodiments, the first administration of the anti-TKVU9 antibody is 2 mg / kg, the second administratio...

Claims

1. A method for treating a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in the T-cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody in a dose of 75-675 mg.

2. The method according to claim 1 for treating a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in the T-cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody in a dose of 100-650 mg.

3. The method according to claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 75-175 mg; or 200-300 mg; or 325-425 mg; or 450-650 mg; or 575-675 mg.

4. The method according to claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 100-150 mg; or 225-275 mg; or 350-400 mg; or 475-525 mg; or 600-650 mg.

5. The method according to claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 115-135 mg; or 240-260 mg; or 365-385 mg; or 490-510 mg; or 615-635 mg.

6. The method of claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

7. The method according to any one of claims 1 to 6, wherein the anti-TRBV9 antibody is administered at least every 3 to 12 months.

8. The method according to any one of claims 1 to 6, wherein the anti-TRBV9 antibody is administered at least every 6 to 12 months.

9. The method according to any one of claims 1 to 6, wherein the anti-TRBV9 antibody is administered at least every 3 months; or the anti-TRBV9 antibody is administered at least every 6 months; or the anti-TRBV9 antibody is administered at least every 9 months; or the anti-TRBV9 antibody is administered at least every 12 months.

10. A method for treating a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in a T-cell receptor, comprising first administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 75-300 mg, a second administration of an anti-TRBV9 antibody at a primary dose of 325-675 mg at least 3 months later, and subsequent administrations of an anti-TRBV9 antibody at a primary dose of 325-675 mg at least every 6 months.

11. The method of treating according to claim 10 a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in the 1-cell receptor, comprising a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 100-275 mg, a second administration of an anti-TRBV9 antibody at a main dose of 350-650 mg at least 3 months later, a third administration of an anti-TRBV9 antibody at a main dose of 350-650 mg at least 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a main dose of 350-650 mg at least every 12 months.

12. The method according to claim 10, comprising a first administration of an anti-TRBV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TRBV9 antibody at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least 3 months later and subsequent administrations of an anti-TRBV9 antibody at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least every 6 months.

13. The method according to claim 10, comprising a first administration of an anti-TRBV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TRBV9 antibody at a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least 3 months later and subsequent administrations of an anti-TRBV9 antibody at a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least every 6 months.

14. The method according to claim 10, comprising a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg, or 620 mg, or 625 mg; or 630 mg at least 3 months later, and subsequent administrations of an anti-TRBV9 antibody at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least every 6 months.

15. A method for treating a disease or disorder mediated by T lymphocytes carrying a TRBV9 segment in a T cell receptor, comprising a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 75-300 mg, a second administration of an anti-TRBV9 antibody at a primary dose of 325-675 mg at least 3 months later, a third administration of an anti-TRBV9 antibody at a primary dose of 325-675 mg at least 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a primary dose of 325-675 mg at least every 12 months.

16. The method of treating according to claim 15 a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in the 1-cell receptor, comprising a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 100-275 mg, a second administration of an anti-TRBV9 antibody at a primary dose of 350-650 mg at least 3 months later, a third administration of an anti-TRBV9 antibody at a primary dose of 350-650 mg at least 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a primary dose of 350-650 mg at least every 12 months.

17. The method according to claim 15, comprising a first administration to a subject in need thereof of an anti-TRBV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TRBV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least 3 months later, a third administration of an anti-TRBV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a basal dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least every 12 months.

18. The method according to claim 15, comprising a first administration of an anti-TRBV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TRBV9 antibody at a main dose of 365-385 mg; or 490-510 mg, or 615-635 mg at least 3 months later and subsequent administrations of an anti-TRBV9 antibody at a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least every 6 months.

19. The method according to claim 15, comprising a first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of the anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg, or 620 mg, or 625 mg; or 630 mg at least 3 months later, a third administration of the anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg, or 620 mg; or 625 mg; or 630 mg at least 6 months later and subsequent administrations of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least every 12 months.

20. The method according to any one of claims 1, 10, 15, wherein the anti-TRBV9 antibody comprises: 1) the variable domain of the heavy chain, containing: (a) HCDR1 with the amino acid sequence of SEQ ID NO: 1, (b) HCDR2 with the amino acid sequence of SEQ ID NO: 2 and (c) HCDR3 with an amino acid sequence selected from the group of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6; 2) a variable domain of the light chain containing: (a) LCDR1 with the amino acid sequence of SEQ ID NO: 7, (b) LCDR2 with the amino acid sequence of SEQ ID NO: 8 and (c) LCDR3 with the amino acid sequence SEQ ID NO:

9.

21. The method according to claim 20, wherein the anti-TRBV9 antibody comprises: 1) the variable domain of the heavy chain, containing: (a) HCDR1 with the amino acid sequence of SEQ ID NO: 1, (b) HCDR2 with the amino acid sequence of SEQ ID NO: 2 and (c) HCDR3 with the amino acid sequence of SEQ ID NO: 4; 2) a variable domain of the light chain containing: (a) LCDR1 with the amino acid sequence of SEQ ID NO: 7, (b) LCDR2 with the amino acid sequence of SEQ ID NO: 8 and (c) LCDR3 with the amino acid sequence SEQ ID NO: 9 22. The method according to claim 20, wherein the anti-TRBV9 antibody is a full-length antibody and is of the human IgG1, IgG2, IgG3 or IgG4 isotype.

23. The method according to claim 20, wherein the anti-TRBV9 antibody comprises a heavy chain variable domain with the amino acid sequence of SEQ ID NO: 14 and a light chain variable domain with the amino acid sequence of SEQ ID NO: 17, or a heavy chain variable domain with the amino acid sequence of SEQ ID NO: 15 and a light chain variable domain with the amino acid sequence of SEQ ID NO:

17.

24. The method according to claim 20, wherein the anti-CRBV9 antibody comprises a heavy chain with the amino acid sequence of SEQ ID NO: 22 and a light chain with the amino acid sequence of SEQ ID NO: 25; or a heavy chain with the amino acid sequence of SEQ ID NO: 23 and a light chain with the amino acid sequence of SEQ ID NO:

25.

25. The method according to any one of claims 1, 10, 15, wherein the disease or disorder mediated by T-lymphocytes carrying the TRBV9 segment in the T-cell receptor is selected from the group: arthropathies, inflammatory bowel diseases, eye diseases, vasculitis, diseases of the circulatory system, kidney diseases, diseases of the digestive system, lymphoproliferative diseases.

26. The method according to any one of claims 1, 10, 15, wherein the disease or disorder mediated by T-lymphocytes carrying the TRBV9 segment in the T-cell receptor is selected from the group: spondyloarthritis, sacroiliitis associated with psoriasis, sacroiliitis associated with inflammatory bowel diseases, undifferentiated oligoarthropathy, juvenile spondyloarthritis / enthesitis-associated arthritis, juvenile ankylosing spondylitis (arthritis associated with enthesitis), juvenile arthritis, undifferentiated juvenile arthritis, ulcerative colitis, Crohn's disease, non-infectious uveitis, anterior uveitis, Behcet's disease, aortitis, fibrosis of the aortic and / or mitral valve leaflets with regurgitation, rhythm disorders, conduction disorders, disorders left ventricular function, pericarditis, myocarditis, IgA nephropathy, celiac disease, T-cell lymphoma, T-cell leukemia.

27. The method according to claim 26, wherein the spondyloarthritis is radiographic axial spondyloarthritis (ankylosing spondylitis), non-radiographic axial spondyloarthritis, axial spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis, spondyloarthritis associated with inflammatory bowel disease, reactive arthritis, undifferentiated peripheral spondyloarthritis.

28. The method according to claim 26, wherein the spondyloarthritis is radiographic axial spondyloarthritis (ankylosing spondylitis), non-radiographic axial spondyloarthritis, axial spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis, spondyloarthritis associated with inflammatory bowel disease, reactive arthritis, or undifferentiated peripheral spondyloarthritis.

29. Use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes that carry a TRBV9 segment within a T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 75-675 mg.

30. The use according to paragraph 29 of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in the T-cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 100-650 mg.

31. The use according to claim 29, wherein the anti-TRBV9 antibody is administered either in a dose of 75-175 mg; or 200-300 mg; or 325-425 mg; or 450-650 mg; or 575-675 mg.

32. The use according to claim 29, wherein the anti-TRBV9 antibody is administered at a dose of 100-150 mg; or 225-275 mg; or 350-400 mg; or 475-525 mg; or 600-650 mg.

33. The use according to claim 29, wherein the anti-TRBV9 antibody is administered at a dose of 115-135 mg; or 240-260 mg; or 365-385 mg; or 490-510 mg; or 615-635 mg.

34. The use according to claim 29, wherein the anti-TRBV9 antibody is administered at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

35. The use according to any of claims 29-34, wherein the anti-TRBV9 antibody is administered at least every 3-12 months.

36. The use according to any of claims 29-34, wherein the anti-TRBV9 antibody is administered at least every 6-12 months.

37. The use according to any one of claims 29 to 34, wherein the anti-TRBV9 antibody is administered at least every 3 months; or the anti-TRBV9 antibody is administered at least every 6 months; or the anti-TRBV9 antibody is administered at least every 9 months; or the anti-TRBV9 antibody is administered at least every 12 months.

38. Use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying a TRBV9 segment in the T cell receptor, wherein the first administration to a subject in need thereof of an anti-TRBV9 antibody is carried out at a dose of 75-300 mg, the second administration of an anti-TRBV9 antibody at a primary dose of 325-675 mg at least 3 months later, and subsequent administrations of an anti-TRBV9 antibody at a primary dose of 325-675 mg at least every 6 months.

39. The use according to paragraph 38 of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in the T-cell receptor, wherein the first administration of the anti-TRBV9 antibody is carried out at a dose of 100-275 mg, the second administration of the anti-TRBV9 antibody at a main dose of 350-650 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350-650 mg at least every 6 months.

40. Use according to paragraph 38, comprising a first administration of an anti-TRBV9 antibody at a dose of 100-150 mg; or 225-275 mg, a second administration of an anti-TRBV9 antibody at a main dose of 350-400 mg; or 475-525 mg, or 600-650 mg at least 3 months later and subsequent administrations of an anti-TRBV9 antibody at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least every 6 months.

41. Use according to paragraph 38, comprising a first administration of an anti-TRBV9 antibody at a dose of 115-135 mg; or 240-260 mg, a second administration of an anti-TRBV9 antibody at a main dose of 365-385 mg; or 490-510 mg, or 615-635 mg at least 3 months later and subsequent administrations of an anti-TRBV9 antibody at a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least every 6 months.

42. The use according to claim 38, comprising a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of an anti-TRBV9 antibody at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 3 months later and subsequent administrations of an anti-TRBV9 antibody at a primary dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least every 6 months.

43. Use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes bearing a TRBV9 segment in a T cell receptor, wherein the first administration to a subject in need thereof of an anti-TRBV9 antibody is carried out at 75-300 mg, the second administration of an anti-TRBV9 antibody at a primary dose of 325-675 mg at least 3 months later, the third administration of an anti-TRBV9 antibody at a primary dose of 325-675 mg at least 6 months later, and subsequent administrations of an anti-TRBV9 antibody at a primary dose of 325-675 mg at least every 12 months.

44. The use according to paragraph 43 of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by I lymphocytes carrying a TRBV9 segment in the I cell receptor, wherein the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 100-275 mg, the second administration of the anti-TRBV9 antibody at a main dose of 350-650 mg at least 3 months later, the third administration of the anti-TRBV9 antibody at a main dose of 350-650 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350-650 mg at least every 12 months.

45. The use according to paragraph 43, the first administration to a subject in need thereof of an anti-TRBV9 antibody is carried out at a dose of 100-150 mg; or 225-275 mg, the second administration of an anti-TRBV9 antibody at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least 3 months later, the third administration of an anti-TRBV9 antibody at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least 6 months later and subsequent administrations of an anti-TRBV9 antibody at a main dose of 350-400 mg; or 475-525 mg; or 600-650 mg at least every 12 months.

46. ​​Use according to paragraph 43, the first administration to a subject in need thereof of an anti-TRBV9 antibody is carried out at a dose of 115-135 mg; or 240-260 mg, the second administration of an anti-TRBV9 antibody at a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least 3 months later, the third administration of an anti-TRBV9 antibody at a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least 6 months later and subsequent administrations of an anti-TRBV9 antibody at a main dose of 365-385 mg; or 490-510 mg; or 615-635 mg at least every 12 months.

47. The use according to paragraph 43, the first administration to a subject in need thereof of the anti-TRBV9 antibody is carried out at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, the second administration of the anti-TRBV9 antibody at a basic dose of 370 mg; or 375 mg; or 380 mg, or 495 mg, or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 3 months later, the third administration of the anti-TRBV9 antibody at a basic dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 6 months later and subsequent administrations of anti-TRBV9 antibody at a basal dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least every 12 months.

48. The use according to any one of paragraphs 29, 38, 43, wherein the anti-TRBV9 antibody comprises: 1) the variable domain of the heavy chain, containing: (a) HCDR1 with the amino acid sequence of SEQ ID NO: 1, (b) HCDR2 with the amino acid sequence of SEQ ID NO: 2 and (c) HCDR3 with an amino acid sequence selected from the group of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6; 2) a variable domain of the light chain containing: (a) LCDR1 with the amino acid sequence of SEQ ID NO: 7, (b) LCDR2 with the amino acid sequence of SEQ ID NO: 8 and (c) LCDR3 with the amino acid sequence SEQ ID NO:

9.

49. The use according to claim 48, wherein the anti-TRBV9 antibody comprises: 1) the variable domain of the heavy chain, containing: (a) HCDR1 with the amino acid sequence of SEQ ID NO: 1, (b) HCDR2 with the amino acid sequence of SEQ ID NO: 2 and (c) HCDR3 with the amino acid sequence of SEQ ID NO: 4; 2) a variable domain of the light chain containing: (a) LCDR1 with the amino acid sequence of SEQ ID NO: 7, (b) LCDR2 with the amino acid sequence of SEQ ID NO: 8 and (c) LCDR3 with the amino acid sequence SEQ ID NO:

9.

50. The use according to claim 48, wherein the anti-TRBV9 antibody is a full-length antibody and is of the human IgG1, IgG2, IgG3 or IgG4 isotype.

51. The use according to claim 48, wherein the anti-TRBV9 antibody comprises a heavy chain variable domain with the amino acid sequence of SEQ ID NO: 14 and a light chain variable domain with the amino acid sequence of SEQ ID NO: 17, or a heavy chain variable domain with the amino acid sequence of SEQ ID NO: 15 and a light chain variable domain with the amino acid sequence of SEQ ID NO:

17.

52. The use according to claim 48, wherein the anti-TRBV9 antibody comprises a heavy chain with the amino acid sequence of SEQ ID NO: 22 and a light chain with the amino acid sequence of SEQ ID NO: 25, or a heavy chain with the amino acid sequence of SEQ ID NO: 23 and a light chain with the amino acid sequence of SEQ ID NO:

25.

53. The use according to any of claims 29, 38, 43, wherein the disease or disorder mediated by T-lymphocytes carrying the TRBV9 segment in the T-cell receptor is selected from the group: arthropathies, inflammatory bowel diseases, eye diseases, vasculitis, diseases of the circulatory system, kidney diseases, diseases of the digestive system, lymphoproliferative diseases.

54. The use according to any one of claims 29, 38, 43, wherein the disease or disorder mediated by T-lymphocytes carrying the TRBV9 segment in the T-cell receptor is selected from the group: spondyloarthritis, sacroiliitis associated with psoriasis, sacroiliitis associated with inflammatory bowel diseases, undifferentiated oligoarthropathy, juvenile spondyloarthritis / enthesitis-associated arthritis, juvenile ankylosing spondylitis (arthritis associated with enthesitis), juvenile arthritis, undifferentiated juvenile arthritis, ulcerative colitis, Crohn's disease, non-infectious uveitis, anterior uveitis, Behcet's disease, aortitis, fibrosis of the aortic and / or mitral valve leaflets with regurgitation, rhythm disorders, conduction disorders, left ventricular dysfunction, pericarditis, myocarditis, IgA nephropathy, celiac disease, T-cell lymphoma, T-cell leukemia.

55. The use according to claim 54, wherein the spondyloarthritis is radiographic axial spondyloarthritis (ankylosing spondylitis), non-radiographic axial spondyloarthritis, axial spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis, spondyloarthritis associated with inflammatory bowel disease, reactive arthritis, undifferentiated peripheral spondyloarthritis.

56. The use according to claim 54, wherein the spondyloarthritis is radiographic axial spondyloarthritis (ankylosing spondylitis), non-radiographic axial spondyloarthritis, axial spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis, spondyloarthritis associated with inflammatory bowel disease, reactive arthritis or undifferentiated peripheral spondyloarthritis.

Images